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ABSTRACT 
 
Head and Neck cancer is the eighth most common cancer worldwide, and squamous cell 
carcinoma represents the majority of the head and neck cancer cases. Despite the 
advancements in therapeutic approaches and treatments to treat this devastating disease, head 
and neck squamous cell carcinoma (HNSCC) still holds one of the worst 5-year survival rates 
compared to other cancer types worldwide, averaging 50%. This underscores the urgent need 
to explore new areas of research and develop new therapeutic drugs and approaches that can 
help improve the survival rate of head and neck cancer patients.  
       Sirtuins (SIRT1–7), class-III NAD-dependent histone deacetylases (HDAC), are 
involved in a myriad of cellular and tissue functions, such as regulating oxidative stress, 
repairing DNA, increasing genomic stability, and modulating cell survival, apoptosis, 
development, metabolism, and aging. Interestingly, sirtuins have emerged as critical 
modulators of different tumorigenic processes, thus highlighting their importance in the area 
of cancer research. In addition, the role of sirtuins in head and neck cancer has not yet been 
investigated. Therefore, because of their emerging role in cancer biology and the need to 
explore novel approaches to improve the fate of head and neck cancer patients, sirtuins were 
explored in the context of HNSCC.  
       In this dissertation work, we show a novel role for sirtuins, and specifically, sirtuin-3 
(SIRT3), in head and neck cancer tumorigenesis. We found that of all the sirtuin family 
members, SIRT3 was overexpressed in oral squamous cell carcinoma (OSCC) in vitro and in 
vivo, compared to other sirtuins.  Downregulation of SIRT3 inhibited OSCC cell growth and 
proliferation, and increased their sensitivity to radiation and cisplatin treatments in vitro. 
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SIRT3 downregulation reduced tumor burden in vivo. In addition, we found a link between 
SIRT3 and anoikis, apoptotic cell death triggered by loss of extracellular matrix (ECM) 
contacts. Our data showed that SIRT3 and receptor interacting protein (RIP) are oppositely 
expressed in OSCC, and that OSCC cells escaped anoikis by forming multicellular aggregates 
or oraspheres to maintain their survival compared to single cells, which underwent anoikis-
mediated cell death. Moreover, anoikis-resistant OSCC cells that possess higher SIRT3 and 
lower RIP expression induced an increased tumor burden and incidence in mice, unlike their 
adherent OSCC cell counterparts. Stable suppression of SIRT3 also inhibited anoikis-
resistance and reduced tumor incidence.   
       To our knowledge, there are no published reports on clinical trials using class-III HDAC 
inhibitors of sirtuins to treat cancer. Therefore, we investigated the effect of a novel SIRT3 
inhibitor, LC-0296, on HNSCC cells that were radio-resistant and originated from patients 
that did not respond to conventional therapies. Interestingly, LC-0296, showed specificity 
toward retarding HNSCC cell survival and enhancing apoptosis, without affecting normal 
human oral keratinocytes. Additionally, LC-0296 not only worked as a single agent on 
HNSCC cells, but also synergistically when combined with either radiation or cisplatin 
treatments. This inhibitory effect of LC-0296 on HNSCC cells was, at least in part, mediated 
by modulation of ROS levels.  
      Lastly, because controversy has emerged in the area of sirtuin biology with regards to the 
role of specific sirtuins in tumorigenesis, we conducted a review of this field. Our findings 
highlight that several sirtuins, including SIRT1 and SIRT3, have unique roles in 
tumorigenesis, which appear to be cell-type and tumor-type specific. Undoubtedly, these 
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features need to be further explored and future studies will help shed additional knowledge in 
this area. 
In summary, this dissertation work highlights a novel role for sirtuins, and specifically, 
SIRT3 in head and neck cancer tumorigenesis. Our data suggest that the development of new 
therapies that would specifically target SIRT3, may have a promising role in the treatment of 
HNSCC, and hopefully improve the survival rate of head and neck cancer patients.  
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CHAPTER I 
 
INTRODUCTION 
 
Problem Statement 
        Head and neck squamous cell carcinoma (HNSCC) is the type of cancer that originates from the oral 
and nasal cavities and sinuses, lips, salivary glands, pharynges, or larynges. Squamous cell carcinoma 
represents the majority of the HNSCC and it is the eighth most common cancer worldwide [1]. It is also 
important to realize that because oral squamous cell carcinoma (OSCC) represents the majority of 
HNSCC cases, we find that in the literature the wording HNSCC and oral cancer is often used 
interchangeably, and their statistics are overlapped. Thus, in this dissertation work, the two words are 
used interchangeably.   
        Although other cancers, such as breast, prostate, and colon cancers occur more frequently than 
HNSCC, the 5-year survival rate of this devastating disease is poor and worse than these other cancers, 
averaging fifty percent [1]. In U.S., one person is estimated to die every hour from oral cancer [1], 
whereas in Canada, three people are expected to die from oral cancer every hour [2]. Despite advances in 
technology and improved therapeutic approaches to treat this disease, shortcomings remain, especially in 
treating aggressive and metastatic diseases and in predicting individual responses to treatment. These 
observations underscore the complexity of this disease and the need for personalized cancer therapy to 
increase the efficacy of treatment in individual cancer patients [3]. Therefore, discovering new prognostic 
markers and pathways that regulate cancer processes in general, and head and neck cancer specifically, is 
crucial to developing better approaches for cancer prevention and treatment.  
The study of sirtuins (SIRT1–7) in cancer tumorigenesis and therapy is an exciting and promising 
new area in cancer research [4,5]. Cancer cells possess six common traits including self-sufficiency in 
growth signals, insensitivity to antigrowth signals, ability to evading apoptosis, promotion of sustained 
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angiogenesis, limitless replicative potential, and ability to invade tissue and metastasize [6]. In addition, 
emerging hallmarks and enabling characteristics in cancer cells include dysregulation of cellular energy 
and avoidance of immune distraction, and the consequences of genomic instability and tumor-promoting 
inflammation are factors that contribute to creating a tumorigenic microenvironment, thus further 
facilitating and supporting the unique features of a cancer cell phenotype [7]. The fact that sirtuins can 
regulate most of these cancer processes, implicates sirtuins as a novel potential therapeutic target to treat 
cancer [8]. However, the role of sirtuins in cancer tumorigenesis has been controversial, and specifically, 
the role of SIRT1 and SIRT3. Thus, further studying this new area of research will advance the field and 
help us to better understand the mechanisms that sirtuins use to regulate the different steps of cancer 
processes. Although, the literature supports an important role for sirtuins in cancer development and 
progression, their role in head and neck cancer has not yet been investigated. In this dissertation work, we 
demonstrated that sirtuins, and specifically SIRT3, is critical to head and heck cancer aggressiveness and 
tumorigenesis. In addition, the modulation of SIRT3 expression levels or the use of SIRT3 specific 
inhibitors increases the sensitivity of HNSCC to radiation and chemotherapeutic treatments, thus 
suggesting SIRT3 as a potential therapeutic for head and neck cancer.  
 
General Hypothesis 
Sirtuins play a critical role in head and neck cancer aggressiveness and tumorigenesis, and sirtuins 
can be used as novel, sole, or adjunctive therapeutic targets to treat head and neck cancer.   
 
Specific Aims 
Our general hypothesis will be tested by addressing the following specific aims: 
Aim 1: To investigate the role of sirtuins in modulating head and neck cancer cell proliferation and 
survival, and whether the modulation of sirtuins would enhance the sensitivity of head and neck cancer to 
radiation and chemotherapeutic treatments.  (Chapter II and Chapter IV) 
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Aim 2: To investigate whether sirtuins can modulate head and neck cancer tumorigenesis in vivo.  
(Chapter II and Chapter III)  
Aim 3: To identify a plausible mechanism by which sirtuins inhibitors can overcome head and neck 
cancer tumorigenesis, thus implicating their use as a potential therapeutics in head and neck cancer. 
(Chapter IV and V)  
Background and Significance 
 
Oral Cancer; Incidence and Risk Factors   
       Oral cancer is a multifactorial and multistep disease that represents an abnormal growth in areas that 
include the tongue, floor of the mouth, lip, and throat, and with the potential to spread to other areas of the 
body. This abnormal cell growth is caused by an imbalance and dysregulation of pro-survival and pro-
apoptotic factors. This ultimately results in the accumulation of changes, which end with the 
transformation of normal cells to malignant cells [9,10]. It is believed that a normal cell needs three to six 
newly acquired mutations to undergo this cellular transformation, and the histological progression of oral 
cancer carcinogenesis reflects the accumulation of these acquired changes [11,12]. These changes start 
with the influence of combined risk factors in the affected individual. In the U.S., approximately 35,000 
people will be diagnosed with oral cancer each year and about 7,600 will die from this disease [13]. Early 
detection is the key to a good prognosis and survival. When oral cancer is diagnosed at an early and 
localized stage, the 5-year survival rate is ~82 %, however, more than half of oral cancer cases are 
diagnosed late after spread to near by tissues, thus dropping the 5-year survival rate to ~ 50% or even to 
28% when there is metastasis to distant organs [13]. Oral cancer is twice as prevalent in men as it in 
women, and African American men have the highest risk of developing oral cancer compared to others in 
the U.S. [13].  
       Risk factors for oral cancer include tobacco and alcohol use, exposure to human papillomavirus 
(HPV), inadequate diet, prolonged sun exposure, family history of the disease, genetic alterations in 
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susceptible individuals, and older age, above forty. Unfortunately, however, 25% of all oral cancer 
patients have no obvious risk factors [14].  
       The incidence of this multifactorial and multistep disease also depends on the combination of 
different risk factors. For instance, the use of both tobacco and alcohol would significantly raise the risk 
compared to either one alone [15]. Thus, chewing tobacco and drinking alcohol would increase the risk of 
oral cancer about 24 fold in a population, such as the population in India [16]. HPV, and specifically 
HPV-16 contributes to 90% of all oropharyngeal cancer types, and it is responsible for the development 
of about 20-30% of all oral cancer cases, especially in the non-smoker or non-alcohol drinking groups 
[14]. Indeed, the combination of both HPV and alcohol consumption work synergistically to increase the 
risk of head and neck cancer patients [17].  
 
Oral Cancer; Biomarkers, Prognosis, and Treatment outcome 
       The identification of oral cancer biomarkers is a crucial tool to enhance diagnosis, prognosis, and 
treatment outcome of this devastating disease. These could help identify genetic and molecular changes 
related to early, intermediate, and late stages of oral carcinogenesis, and could also be used to evaluate the 
efficacy and safety of different treatment measures, thus helping the development of personalized cancer 
therapy for each patient.  Because of the complexity of the oral cancer process, there is no doubt that 
looking for a single biomarker to assess the previously mentioned parameters is not enough; however, the 
use of several plausible biomarkers that would control this disease in a specific patient would be a logical 
approach. Thus, research aimed at discovering these cancer biomarkers will help us to better understand 
the biology of this disease and enhance future treatment of patients with oral cancer [18]. Several methods 
have been used to elucidate cancer biomarkers to assess prognosis and treatment outcomes for oral cancer 
patients. These include the use of DNA-microarray technology to obtain gene expression profiling to help 
identify oral cancer specific signatures [19,20,21], immunohistochemistry and enzyme-linked 
immunosorbent assay (ELISA) assays to look for protein expression in OSCC tissue samples. In addition, 
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proteomic methods such as 2-D gel electrophoresis and mass spectrometry have been used to assess body 
fluid proteins in saliva and plasma [22,23]. These methods look for changes in key regulatory 
genes/proteins, including tumor promoters or suppressors, in oral cancer carcinogenesis, or identify 
epigenetic changes, including methylation or acetylation of specific proteins or tumor suppressor genes, 
such as p16, p53, and E-cadherin [18,24,25]. Studies in this area showed that the expression levels of p16, 
a gene that controls cell cycle progression in the G1 phase, is decreased in OSCC and seems to be critical 
for malignant progression when deleted. Decreased levels of p16 or deletion of p16 were also associated 
with increased recurrence rates, metastasis, and reduced survival rate [26]. The tumor suppressor p53, is 
frequently mutated in more than 50% of OSCC, and these mutations were associated with high expression 
and accumulation of p53 when assessed with immunohistochemistry. This positive expression has been 
reported in about 50% of adjacent non-tumor tissues, suggesting that p53 mutations are early events in the 
course of OSCC carcinogenesis, and they may be useful biomarkers for early detection [27]. The low 
expression of the adhesion molecule E-cadherin was correlated with poor prognosis and survival in 
OSCC. In addition, reduced levels of E-cadherin were a predictive biomarker for lymph node metastasis 
in oral cancer patients [28].  Epigenetics is also an emerging area of research that explores the mitotically 
and/or meiotically heritable changes in gene functions that cannot be explained by changes in DNA 
sequence. Interestingly, the two most important risk factors in oral cancer carcinogenesis, tobacco and 
alcohol consumption have been shown to directly modulate epigenetic factors and work synergistically to 
increase the risk of oral carcinogenesis [24,29]. The tumor suppressor p73, a protein related to p53 
structurally and functionally, was found to be inactivated with methylation in OSCC and this silencing 
was associated with OSCC progression [30]. Furthermore, methylation of p16 and E-cadherin was 
associated with the duration of smoking and alcohol consumption, and increased tumor size and potential 
metastasis [29]. As previously mentioned, one strongly emerging risk factor for oropharyngeal cancer is 
exposure to HPV [31]. Interestingly, although the association between HPV and OSCC development is 
strong, some investigators consider this type of tumor of a distinct clinical and pathological nature 
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because these tumors, surprisingly, respond better to conventional treatments and have a better prognosis 
and survival rate. Therefore, HPV is considered a new prognostic biomarker for head and neck cancer 
[32,33]. Additionally, chromosomal aberrations such as amplifications, deletions, and structural 
rearrangements are another important hallmarks of oral cancer carcinogenesis [18]. These acquired events 
are commonly associated with loss of heterozygosity (LOH) in chromosomes 3 and 9 in the early stages 
of normal cell transformation. The events can be assessed with comparative genomic hybridization and 
microsatellite panel assessment studies. These are developing and promising areas of research aimed at 
discovering prognostic markers and patients at high risk for developing the disease [18,34]. 
       The current gold standard for prediction of prognosis and for decision of treatment options is based 
on the TNM classification: tumor size (T), regional lymph nodal involvement (N), and the presence or 
absence of distant metastasis (M). Although this system is not perfect and has its limitations [35,36], it is 
still widely used and accepted for planning, prognosticating, and comparison of treatment outcomes. For 
example, tumors of similar size may behave differently due to their genomic and biological background 
dysregulation differences. Based on the TNM system, the tumor will then be assigned, a stage (I-IV), 
which will determine the treatment modality used in each specific case [18,37]. Surgical intervention is 
still the primary treatment option when the lesion is localized, however with advanced cases and difficult 
operating areas, radiation and chemotherapy is essential. Unfortunately, this type of treatment always 
increases the side-effects and morbidity of the disease. Nguyen and Yueh found 1-year survival rates of 
60% (stage I) and 32% (stage IV) in patients with recurrence or secondary primary cancer [36]. This 
highlights the importance of early detection and diagnosis of the disease, and the urgent need for valid 
and more reliable biomarkers to better assess the nature and behavior of each specific lesion. In general, 
increased tumor thickness, extracapsular spread, poor histological tumor differentiation, unclear surgical 
margins, and angiogenesis enrichment, are all predictive factors of a poor prognosis and reduced survival 
rate [37,38]. In addition, Murthy et al. demonstrated that the location of the OSCC and the selected mode 
of treatment would also affect the prognosis and survival rate in advance stages of oral cancer [39]. For 
7"
"
example, superior outcomes were achieved in cases treated with surgery followed by post-operative 
radiation (PORT) compared to radiation alone. In addition, the lip and hard palate showed better 
outcomes and response to treatment than tongue and floor of the mouth sites. This emphasizes the 
importance of adapting the treatment to the tumor stage and location [39].  
       In summary, the current system used for OSCC tumor staging, treatment planning, and 
prognostication, has limitations. The urgent need for discovering valid and reliable biomarkers to control 
this disease and assess the previously mentioned parameters is ever present. These biomarkers may help 
better evaluate preventive and therapeutic measures, aid in the early diagnosis of the disease, and reduce 
the number of patients that would undergo either unnecessary or deficient treatment regimens, and 
hopefully help advance the field toward the development of personalized cancer therapy. These 
biomarkers can then either replace or add to the current TNM system and become part of routinely used 
approaches for diagnosis, prognosis and treatment planning.  
 
Sirtuins and Cancer; an Overview 
       Sirtuins (SIRT1–7) are the mammalian homologues of the silent information regulator 2 (Sir2) first 
discovered in Saccharomyces cerevisiae as an NAD+-dependent histone deacetylase (HDAC). They are 
classified as class III HDACs: they require NAD+ as a cofactor to exert their biological function. They 
contain an evolutionarily conserved core domain, which is essential for their activity as NAD-dependent 
deacetylases or ADP-ribosyltransferases [40,41]. Sirtuin biology is complex, and sirtuins are widely 
expressed in normal tissues [42]. They are involved in a myriad of cellular and tissue functions, such as 
regulating oxidative stress, repairing DNA, increasing genomic stability, and modulating cell survival, 
apoptosis, development, metabolism, aging and longevity [4,5]. Some sirtuins are located in different 
cellular compartments (Fig. 1.1). Those in the same compartment, such as the mitochondrial SIRT3, 4, 
and 5, have different sequences, and thus, unique and diverse cellular functions, and can interact with 
different targets [5,40,41].  
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SIRT1 is the best-characterized member of the mammalian sirtuins. It is located predominately in the 
nucleus and modulates cellular stress and survival by deacetylating p53 [43,44], FOXO, and Ku70 
[45,46], thus promoting tumorigenesis. SIRT1 is thought to have a role in skin, colon, breast and lung 
cancer, via one or more of these mentioned targets [47,48,49,50,51]. It also regulates vascular endothelial 
homeostasis, thereby controlling angiogenesis and vascular function, [52]. Thus, it is likely crucial in 
regulating cell survival, and its functions may contribute to cancer tumorigenesis.  
On the other hand, other studies support a tumor suppressor role for SIRT1 [53,54,55]. For example, 
SIRT1 mutant mice possess an impaired DNA repair response, genomic instability, and increased 
incidence of tumorigenesis. Moreover, SIRT1 levels were lower in breast cancer and hepatic cell 
carcinoma than in normal controls [54]. These studies highlight the discrepancy in the literature about the 
biological functions of SIRT1 and underscore the complexity of sirtuin biology (See reviews by Deng et 
al. and Lim et al. [56,57]).  
 SIRT2 is found in the cytosol, where it colocalizes with microtubules and deacetylases α-tubulin 
[58]. It controls cell-cycle progression [59] and is downregulated in human gliomas, suggesting a tumor 
suppressor role in brain cancer [60].  
The gene for the nuclear protein SIRT6 is located on chromosome 19p13.3; a region frequently 
affected by chromosomal alterations in acute leukemia [61]. In addition, SIRT6-deficient mice possess an 
aging-like phenotype and genomic instability [62,63].  
SIRT7, which is localized in the nucleolus and functions as a positive regulator of RNA polymerase I-
mediated transcription, is required for cell proliferation and survival [64]. SIRT7 gene is located on 
chromosome 17q25.3; a region frequently associated with chromosomal alterations in leukemias and 
lymphomas [65]. SIRT7 is also upregulated in breast and thyroid cancers [66,67,68].  
       The remaining three sirtuins, SIRT3, SIRT4, and SIRT5, are mitochondrial sirtuins [42,69]. Although 
SIRT4 lacks deacetylation activity, it has weak ADP-ribosyltransferase activity [70,71] and plays an 
important role in insulin regulation [72]. SIRT4 knockout mice are viable, fertile, and display no 
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phenotype abnormalities, compared to wild-type littermates, but show increased levels of insulin secretion 
[70]. In contrast to SIRT1 and SIRT3, SIRT4 activity is downregulated by calorie restriction (CR) [70]. 
SIRT5 has less deacetylase activity than SIRT1-3 [73] and remains the least-characterized sirtuin. SIRT5 
is located on chromosome 6p23, an area linked to numerous abnormalities associated with malignant 
diseases, such as acute myeloid leukemia [74]. In contrast to SIRT4- and SIRT5-deficient mice, SIRT3-
deficient mice show greater mitochondrial hyperacetylation than wild-type mice, suggesting that SIRT3 is 
a key mitochondrial deacetylase [75].  
       The controversy over whether SIRT1 works as tumor promoter or suppressor, can also be applied to 
SIRT3. SIRT3 exerts a prosurvival role in multiple cancer pathways. The tumor suppressor, p53 was 
recently identified as a new target for SIRT3 deacetylation in bladder cancer [76]. SIRT3 rescued p53-
induced growth arrest in human bladder tumor–derived EJ-p53 cells, supporting a prosurvival role for 
SIRT3 [76]. Ashraf et al. reported that increased transcriptional levels of SIRT3 were associated with 
lymph node–positive breast cancer, and SIRT3 expression was significantly higher in these samples than 
normal breast biopsies [66]. Additionally, SIRT3 is overexpressed in metabolically active tissues, such as 
the heart, where SIRT3 protects against genomic and stress-mediated apoptosis, at least in part, via ROS 
reduction and increases in Ku70-Bax interactions [77,78] These can be mechanisms by which cancer cells 
that overexpress SIRT3 can similarly resist cell death. This was indeed demonstrated by the same group 
in the HeLa cervical cancer cell line [77]. In contrast, other reports support a proapoptotic role for SIRT3. 
SIRT3 induces growth arrest and apoptosis in several colorectal carcinoma and osteosarcoma cells and in 
non-cancer human cell lines, such as retinal epithelial and lung fibroblast cells [79]. This action is 
mediated, in part, by SIRT3 modulation of the JNK2 signaling pathway in these cell lines [79]. In 
leukemia cell lines, treatment with Kaempferol, a flavonoid that auto-oxidizes and generates ROS, 
induces apoptosis via increasing Bax and SIRT3 levels and activating caspase-3 cascades [80]. Moreover, 
SIRT3 demonstrates a tumor suppressor function in breast, colon carcinoma and osteosarcoma cells, via 
suppressing ROS, HIF1-α and its targeted genes [81,82,83].  
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      It seems that SIRT1 and SIRT3 may play a dual role. Their functions may vary in different normal 
and tumor tissues and may be cell- and tumor-type specific. Therefore, their role in specific cell types 
must not be generalized, but should be examined separately under different cellular events, and 
specifically in each cancer type to determine whether it functions as a tumor promoter or suppressor [49].  
 
Sirtuins as Potential Therapeutic Targets for Cancer  
       Several studies have implicated sirtuins as novel therapeutic targets for many age-related diseases, 
including cancer, but how sirtuins are involved in cancer is still not clear and controversial. A better 
understanding of how individual sirtuins are involved in different cancer types is important for assessing 
their potential in possible therapies. Sirtuins seem to be involved in tumorigenesis, and thus, sirtuin 
inhibitors/modifiers might have therapeutic benefit. Several inhibitors and activators of sirtuins have been 
tested in different cancer cell lines, but few have been tested in vivo [84]. The sirtuin inhibitors, sirtinol 
and splitomicin, induced senescence-like growth arrest in breast and lung cancers [85]. NAM, another 
sirtuin inhibitor, induced apoptosis in lung cancer [43]. Treatment of B-cell lymphoma cells with 
cambinol, a SIRT1 inhibitor, inhibited tumor cell growth and induced apoptosis in vitro, and reduced 
tumor size compared to controls in vivo [86]. Moreover, cambinol sensitized lung cancer cells to the 
DNA-damaging agent etoposide, thus inducing cell death and etoposide-induced cell-cycle arrest [86] 
(See review by Balcerczyk et al. [87]).  
Resveratrol, a polyphenol phytoalexin and natural component found in the skin of red grapes and red 
wine, works as an activator of sirtuins and possesses diverse natural therapeutic benefits, including 
cardiac protection, anti-inflammatory and anti-carcinogenic effects, preventing obesity, and promoting 
longevity [88,89]. These therapeutic benefits seem to work, at least in part, by activating SIRT1 and 
SIRT3, although it is not yet clear whether these effects are mediated by direct or indirect mechanisms 
[88,89,90,91]. Interestingly, resveratrol modulates both survival and death signals, depending on the 
administered dose in vivo [92]. At low doses (2.5 or 5 mg/kg for 14 days in rats), resveratrol provided 
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cardiac protection and lower levels of apoptosis than controls. In contrast, at high doses (25 or 50 mg/kg), 
resveratrol hindered cardiac function and promoted apoptosis of cardiomyocytes. The former effect was 
mediated by augmenting survival signaling pathways, including p-Akt, NFκB, and Bcl-2 activation. The 
later was mediated by switching on the death program by repressing the same pathways [92]. Moreover, 
resveratrol is the most studied sirtuin activator in cancer prevention. Many studies have shown resveratrol 
to be a natural anticarcinogenic agent, modulating different stages of cancer, including initiation, 
promotion, and progression in neuroblastoma, hepatoma, breast, lung, pancreatic, and prostate cancers in 
vitro or in vivo [93,94]. However, many of these studies yielded contradictory results even in the same 
tumor type. The reasons for these discrepancies could be due to the different experimental approaches 
used to examine resveratrol. For instance, some data were collected from mice and others from rats. Some 
studies used animal carcinogenesis models with different genetic backgrounds, others used different doses 
of resveratrol, and yet others used different time frames for drug administration. Resolving these 
discrepancies would be very helpful. In addition, these drugs are all generalized inhibitors or activators of 
several sirtuin family members. Thus, some redundancy or even opposing actions of some sirtuin 
functions may be expected. Furthermore, different tumors have different genetic backgrounds that differ 
from one person to another. This diversity may explain why one patient responds well to a specific 
treatment but another patient with the same type of cancer does not.  
Therefore, the rapidly evolving era of personalized and targeted approaches holds great promise for 
the future of cancer therapy. Foe example, looking for specific cancer profile signatures by using gene 
microarray technology as an example [21], and then identifying key dysregulated pathways for targeted 
therapy, would be beneficial and result in less oral complications than using conventional therapeutic 
approaches alone [95,96]. Some of these targeted therapies currently used in phase I-III to trials to treat 
oral cancer patients, includes the use of anti-tumor monoclonal antibodies, small molecules, and signal 
transduction receptor inhibitors [95]. For example these include the epidermal growth factor receptor 
inhibitor (EGFR), erlotinib, and the anti-vascular endothelial growth factor (VEGF) antibody, 
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bevcizumab (Avastin). The former is a small molecule tyrosine kinase inhibitor (TKIs) of EGFR, and the 
latter is an antibody that inhibits angiogenesis, thus preventing tumor growth by neutralizing VEGF 
activity. Both are used in combination to treat patients with recurrent and metastatic OSCC. This 
combination is well tolerated and shows promising results [97]. In addition, the use of RNA interference 
(RNAi) as a specifically targeted therapeutic approach may also be useful especially in combination with 
conventional treatments. Currently, studies using RNAi are still in early stages of clinical trials. RNAi has 
been tested in different types of cancer, such as lung, advanced liver, and chronic myeloid leukemia. This 
demonstrates the usefulness of targeted gene knockdown as a potential therapeutic approach (See review 
by Phalon et al. [98]).  
Class-I and II HDAC inhibitors have been tested in phase-I and II clinical trials with or without 
conventional chemotherapeutic drugs. The agents were well tolerated with low toxicity and yielded 
promising results. Some of the agents used include phenyl acetate, suberoylanilide hydroxamic acid 
(SAHA), and Trichostatin (TSA) to treat patients with solid tumors, hematologic malignancies, and 
advanced leukemias [99]. In head and neck cancer, SAHA and TSA show selective inhibition of cell 
growth and induction of apoptosis compared to normal and premalignant cells [100,101]. In addition, the 
combination of SAHA and cisplatin chemotherapeutic drugs possess synergetic cytotoxicity effects 
against OSCC cells, at least in part, by enhancing ROS production [102].  
To our knowledge, there are no published reports on clinical trials using class-III HDAC inhibitors of 
sirtuins to treat cancer. However, class-III HDAC activators of sirtuins such as resveratrol are currently in 
early stages of clinical trials, and have been tested for safety and potential treatment of age-related 
diseases such diabetes, neurodegenerative disorders and cancer (See references [103,104] for ongoing and 
published clinical trials).  
       In summary, head and neck cancer still holds one of the worse survival rates compared to other 
cancer types worldwide. This underscores the need for discovering new areas of research that can help 
improve the survival rate of head and neck cancer patients. The role of sirtuins (SIRT1-7) in cancer has 
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emerged to be an interesting and important area of cancer research, however, because of the controversy 
in this area, there is a lot yet to be revealed. In addition, the role of sirtuins in head and neck cancer has 
not yet been investigated, therefore, it will be interesting to determine if this field of study could hold a 
new hope for patients suffering from this devastating disease.  
 
Organization of Thesis Contents 
 
In Chapter II, the initial evidence of the potential role of sirtuins (SIRT1-7) in oral cancer 
tumorigenesis is discussed. Specifically, the evidence showing that SIRT3 is a key regulator of OSCC cell 
survival and proliferation, and that SIRT3 inhibition enhances the sensitivity of oral cancer cells to 
radiation and chemotherapeutic treatments is demonstrated. In addition, evidence that SIRT3 controls the 
aggressiveness of oral cancer tumorigenesis in vivo is also shown.  
       In Chapter III, it was demonstrated previously by our group that receptor interacting protein (RIP) 
has a role in controlling anoikis in oral cancer. In this work, a potential crosstalk between RIP and SIRT3 
in controlling anoikis resistance and tumorigenesis is demonstrated in vitro and in vivo.  
      In Chapter IV, the role of SIRT3 in controlling HNSCC cell survival, proliferation, and apoptosis, is 
further demonstrated, by testing the effect of a novel SIRT3 inhibitor against HNSCC cells, and the 
mechanism by which this SIRT3 inhibitor may, at least in part, affect HNSCC cell survival, proliferation, 
and apoptosis, will be discussed.  
In Chapter V, because the role of SIRT3 in cancer is controversial, the role of SIRT3 as a tumor 
promoter or suppressor in cancer is discussed.  
In Chapter VI, summary of major findings and future directions of this dissertation work is 
presented.  
"
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Figure 1.1: Sirtuins subcellular localization: SIRT1 is predominantly located in the nucleus, and also in 
the cytosol. SIRT2 is localized in the cytosol. SIRT3, SIRT4, and SIRT5 are mitochondrial proteins, but 
SIRT3 may also be found in the nucleus and cytosol under different cellular events.  SIRT6 and SIRT7 
are localized in the nucleus and nucleolus, respectively. 
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CHAPTER II 
 
SIRTUIN-3 (SIRT3), A NOVEL POTENTIAL THERAPEUTIC TARGET FOR ORAL CANCER 
 
ABSTRACT
  
BACKGROUND: Several sirtuin family members (SIRT1-7), evolutionarily conserved NAD-dependant 
deacetylases, play an important role in carcinogenesis. However, their role in oral cancer has not yet been 
investigated. Therefore, the aim of this study was to investigate whether sirtuins play a role in oral cancer 
carcinogenesis. METHODS:  The expression levels of all sirtuins in several oral squamous cell 
carcinoma (OSCC) cell lines compared with normal human oral keratinocytes, and found SIRT3 was 
highly expressed. Therefore, tissue microarrays were used to evaluate the clinical relevance of this 
overexpression. SIRT3 downregulation in OSCC cell proliferation and survival was investigated and 
analyzed by cell proliferation and cell viability assays. Ionizing radiation and cisplatin were used to 
investigate whether SIRT3 downregulation can increase the sensitivity of OSCC to both treatments. To 
further assess the in vivo role of SIRT3 in OSCC carcinogenesis, we used a floor-of-mouth oral cancer 
murine model to study the effect of SIRT3 downregulation on OSCC tumor growth in immunodeficient 
mice. RESULTS: We show for the first time that SIRT3 is overexpressed in OSCC in vitro and in vivo, 
compared with other sirtuins.  Downregulation of SIRT3 inhibited OSCC cell growth and proliferation, 
and increased its sensitivity to radiation and cisplatin treatments in vitro. SIRT3 downregulation reduced 
tumor burden in vivo. CONCLUSIONS: Our findings reveal a novel role for SIRT3 in oral cancer 
carcinogenesis as a promoter of cell proliferation and survival, thus implicating SIRT3 as a new potential 
therapeutic target to treat oral cancer.  
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Introduction 
       Oral cancer is the eighth most common cancer worldwide, and oral squamous cell carcinoma (OSCC) 
accounts for more than 90% of all oral malignancies 1. The 5-year survival rates range from 34- 62.9%, 
which have not changed for decades 2 . This underscores the need for new therapeutic targets to treat oral 
cancer. Recently, several members of the sirtuin family (SIRT1-7), the human homologues of the Sir2 
gene in yeast, were found to play an important role in carcinogenesis 3. Sirtuins function as either NAD-
dependant deacetylases or ADP-ribosyl transferases, which explains their involvement in a diversity of 
cellular functions, including regulation of oxidative stress, increasing genomic stability, cell survival, 
development, metabolism, aging and longevity 4, 5. SIRT1, the best characterized family member, targets 
several key regulators that affect carcinogenesis, such as the tumor suppressor p53, the DNA repair 
protein Ku70, and the pro-apoptotic protein FOXO 3, 6.  Current literature supports a pro-survival role for 
SIRT1 in colon, breast and lung cancer, through one or more of these previously mentioned targets 3. In 
contrast, other reports support that SIRT1 may act as a tumor suppressor 7, 8.  
       Although much is known about SIRT1, less is known about other mammalian Sir2 homologues such 
as SIRT3. SIRT3, the only member linked to longevity in humans 9-11, is a mitochondrial protein 12-18, that 
is overexpressed and associated with node-positive breast cancer 19. Moreover, during stress, SIRT3 
levels increase, protecting cells from apoptosis. Thus, like SIRT1, SIRT3 may bind and deacetylate Ku70, 
promoting Ku70-Bax interactions and attenuating apoptosis in cardiomyocytes 20. In addition,  
mitochondrial SIRT3 is required for Nampt, a stress and diet-responsive regulator of mitochondrial 
NAD+, to promote cell survival during genotoxicity 21. More recently, SIRT3 was found to abrogate p53 
activity, thus preventing growth arrest and senescence in bladder carcinoma cells 22. These findings 
suggest a role for SIRT3 in carcinogenesis, however, the role of sirtuins has not been investigated in oral 
cancer. Therefore, the aim of this study was to elucidate the role of sirtuins in oral cancer.  
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Materials and Methods 
Cell lines and culture. Human OSCC cell line HSC-3 was provided by Randy Kramer (University of 
California, San Francisco). OSCC cell lines, UM-SCC-1 and UM-SCC-17B were from Tom Carey 
(University of Michigan). Primary human keratinocytes were derived from normal gingival tissues 
discarded from periodontal surgical procedures and approved by the University of Michigan IRB. OSCC 
cells were maintained in DMEM (Gibco) supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin. Primary human oral keratinocytes were maintained in EpiLife medium (Cascade 
Biologics).  
 
Transient transfection. Cells were transiently transfected with small interfering RNA (siRNA, 150 nM, 
a pool of 3 target-specific siRNA) against SIRT3 or a non-targeting control (Santa Cruz Biotechnology), 
in serum-free medium containing Lipofectamine Plus (Invitrogen). Transfection efficiency was assessed 
by Western blotting. 
 
Stable transfection. UM-SCC-17B cells were transduced with SIRT3-shRNA (sc61555-vs) or 
scrambled-shRNA (sc-108084, Santa Cruz Biotechnology) lentiviral particles in 0.5ml of serum-free 
media, then selected in 10 µg/ml puromycin for an additional 10 days (sc-108071, Santa Cruz 
Biotechnology). Surviving cell colonies were picked and propagated before testing for SIRT3 expression. 
 
Cell proliferation and colony formation assays. To determine the effect of Sirtinol, NAM, ionizing 
radiation (IR) and cisplatin on cell proliferation, the QUANT Cell Proliferation Assay Kit was used 
according to manufacturer’s instructions (Invitrogen). For colony formation assays, OSCC cells were 
transfected as mentioned above and cultured for one week. Colonies were stained with 0.5% crystal violet 
and colonies containing greater than 50 cells were counted.  
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Apoptosis cell death detection by ELISA. To measure apoptosis in vitro, a DNA-fragmentation ELISA 
assay was used according to manufacturer’s instructions (Roche Diagnostics, Indianapolis, IN, USA). 
 
Immunoblot analysis. To evaluate the expression levels of sirtuins in OSCC cells compared with normal  
primary human keratinocytes or the transfection/transduction efficiency of cells, cells were treated as 
described above or in figure legends, washed once with PBS, and lysed in RIPA lysis buffer (R0278, 
Sigma) that contained 1% protease inhibitor cocktail (P8340, Sigma) on ice for 30 min. Lysates were 
adjusted for protein concentration with the BCA protein assay kit (Bio Rad). Lysate proteins were 
resolved by SDS-PAGE and transferred to Immobilon-P membranes (Millipore). Western blotting was 
performed with primary antibodies and horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG 
antibodies and developed with the ECL-Plus detection system (Pierce).!Antibodies for SIRT1 (sc-15404) 
and SIRT2 (sc-20966) were from Santa Cruz Biotechnology. The SIRT3 antibody (2627) was from Cell 
Signaling. Antibodies to SIRT4 (IMG-3580), SIRT5 (IMG-479), and SIRT7 (IMG-425) were from 
IMGENEX. The SIRT6 antibody (AP6245a) was obtained from ABGENT.  To demonstrate equal protein 
loading, membranes were stripped and reprobed with an anti-β-actin antibody (sc-1615, Santa Cruz 
Biotechnology).  
 
Tissue Microarrays. Immunohistochemical analyses were performed to determine the expression of 
SIRT3 and SIRT7 in human normal and OSCC tissues, using OSCC tissue microarrays (OR601 and 
HN241, Biomax.us) and the histostatin kit (95-6143, Zymed lab) as per the manufacturer’s instructions. 
Antibodies to SIRT3 (AP6242a) and SIRT7 (AP6246a) were obtained from ABGENT. Staining 
intensities were graded in a blinded manner as low or high by a pathologist. 
 
Immunodeficient mouse model of human head and neck squamous cell carcinoma. Three-week-old 
athymic nude mice (NCr-nu/nu strain; NCI, Frederick, MD, USA), that weighed 20 and 25 g were 
anesthetized by intraperitoneal injection with 100 mg/kg ketamine and 10 mg/kg xylazine. The human 
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OSCC cell line UM-SCC-17B stably expressing SIRT3-shRNA or scrambled-shRNA was grown to 70% 
confluence prior to injection. We used a murine floor-of-mouth model, which we previously optimized to 
produce 4-5 mm tumors, corresponding to a palpable tumor volume of 35-60 mm3, within ~2-4 weeks 
post-injection 23. In brief, cells were suspended in DMEM,  chilled on ice, and resuspended in an equal 
volume of growth factor reduced Matrigel (BD Biosciences, San Jose, CA, USA; Cat #354230), to a final 
concentration of 2.5 x 105/ 0.1 ml. The cell/matrigel solution was chilled on ice prior to injection, and 
each animal was injected with an equal number of OSCC cells (2.5 x 105) submucosally in the floor of the 
mouth. After three weeks, mice were euthanized and digital caliper was used to determine the tumor 
volume using the formula:  a x a x b/2, where a is the smaller dimension.  
 
Statistical analysis. Values were expressed as means ± SD. Intergroup differences were determined by 
two-way analysis of variance (ANOVA) and Scheffe’s multiple-comparison test. Statistical significance 
was defined as *p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. For tissue microarray analyses a chi-square test was 
employed. For the in vivo studies, independent t- test with unequal variances was used. All experiments 
were repeated at least three times.  
Results 
SIRT3 is overexpressed in oral squamous cell carcinomas. To determine whether sirtuins play a role in 
OSCC, we examined the protein levels of all sirtuins (SIRT1-7) in several OSCC cell lines (HSC-3, UM-
SCC-1 & UM-SCC-17B) and compared those cells with normal primary human oral keratinocytes (Fig. 
2.1A). Only SIRT3, and to a lesser extent SIRT7, were overexpressed in all three cell lines compared with 
primary keratinocytes. To further examine the in vivo and clinical relevance of SIRT3 and SIRT7, 
immunohistochemical analyses were performed for both sirtuins using tissue microarrays of OSCCs (Fig. 
2.1 and Fig. 2.S1). A total of 52 samples, containing 42 malignant and 10 normal tissue samples were 
analyzed. Grade 1, 2, &3 tumors from the tongue, cheek, gingiva, lip and oral mucosa were analyzed 
along with normal tissue from the tongue, palate, and gingiva (Table 2.1 and Table 2.S1). Staining 
!
!
27!
intensity was assessed as low or high (Table 2.1 and Table 2.S1). SIRT3 expression was significantly 
higher in OSCC tissues compared with normal tissues (Fig. 2.1B; Table 2.1, *p≤ 0.05), whereas SIRT7 
expression levels were not significantly different (Fig. 2.S1A; Table 2.S1, p≥ 0.05). SIRT3 staining 
intensity data from Table 1 were graphically illustrated (Fig. 2.1C). SIRT3 exhibited an opposite pattern 
of expression between OSCC and normal tissues (Fig. 2.1C, top). Furthermore, because the tongue 
accounts for 30% of oral malignancies 1, we specifically examined tongue samples separately. SIRT3 
staining intensity was significantly higher in OSCC tongue samples compared with normal tongue tissues 
(Fig. 2.1C, bottom; Table 2.1, *p≤ 0.04).  
 
Sirtuin inhibitors, Sirtinol and NAM, inhibit cell growth and proliferation, and induce apoptosis. 
Having established that sirtuins, and specifically SIRT3 was associated with OSCC, we next explored the 
role of sirtuins in modulating OSCC cell growth and proliferation. To this end, we tested the commonly 
used sirtuin inhibitors, sirtinol and nicotinamide (NAM), which inhibited cell growth in breast and lung 
cancers 24, 25. Both inhibitors inhibited cell growth and proliferation in OSCC cells (Fig.  2.2A). In 
addition, both inhibitors induced apoptosis in OSCC cells compared with untreated controls as 
determined by cell death ELISA assays that measure DNA fragmentation (Fig. 2.2B).  
 
SIRT3 downregulation inhibits cell growth and proliferation, and promotes apoptosis in OSCC 
cells. To gain further insight into the effects of SIRT3 on OSCC cell survival and proliferation, we 
performed colony formation assays in the context of SIRT3 inhibition with siRNA. As with cell growth 
studies, SIRT3 downregulation inhibited colony formation in OSCC cells compared with controls (Fig. 
2.3A). Furthermore, downregulation of SIRT3 also promoted apoptosis in OSCC cells, mimicking the 
effect of Sirtinol and NAM on these cells (Fig. 2.3B).  
 
SIRT3 downregulation enhances the sensitivity of OSCC cells to radiation and cisplatin-induced 
cytotoxicity. Because radiation is the primary treatment modality in head and neck cancer, and cisplatin 
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is one of the first chemotherapeutic drugs used to treat OSCC 26, we asked whether SIRT3 
downregulation with siRNA enhances the sensitivity of OSCC cells to radiation and cisplatin. 
Cytotoxicity assays were performed first to optimize ionizing radiation (IR) and cisplatin (CDDP) doses, 
and determine the IC50 for both treatments in all cell lines (data not shown). Indeed, downregulation of 
SIRT3 with siRNA enhanced the sensitivity of UM-SCC-1 and UM-SCC-17B cell lines to both 
treatments compared with untreated controls and cells treated with radiation or cisplatin alone (Fig. 2.4).  
 
SIRT3 downregulation reduces OSCC tumor burden in vivo. To further demonstrate the role of 
SIRT3 in OSCC carcinogenesis in vivo, we used a murine floor-of-mouth model that mimics human 
OSCC 23, 27. The UM-SCC-17B cell line was selected for examination in this model because of its highly 
aggressive nature, resistance to radiation therapy, and because it commonly produces tumors in this in 
vivo model 23. The UM-SCC-17B cell line was used to produce stable clones expressing downregulated 
levels of SIRT3 using SIRT3-shRNA, and scrambled-shRNA was used for controls (Fig. 2.5A). SIRT3-
shRNA (clone 4) and Scrambled-shRNA (clone 1) were selected for the in vivo injections. In agreement 
with our in vitro data, our mouse model data show that downregulation of SIRT3 in OSCC cells 
significantly inhibited tumor growth in vivo (Fig. 2.5B). Specifically, mean tumor volume for the SIRT3 
downregulated group and control group was 26.948 (mm3) and 112.325 (mm3), respectively (Fig. 2.5B; 
Table 2.2, **p≤ 0.001).  
 
Discussion 
We report for the first time a role for sirtuins and specifically, SIRT3 in OSCC carcinogenesis. 
There is an emerging role for several sirtuins in carcinogenesis 4. However, their role in oral cancer has 
not been investigated. Thus, we explored their potential role in OSCC by evaluating their expression level 
in several OSCC cell lines compared with normal human oral keratinocytes. Our initial finding that 
SIRT3 was overexpressed in OSCC cells compared with normal human oral keratinocytes, led us to 
hypothesize that SIRT3 might play a role in OSCC carcinogenesis. Thus, to further explore the clinical 
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relevance of this overexpression, we used tissue microarray analyses of OSCC tissues. The high 
expression of SIRT3 in OSCC tissues compared with normal tissues, further supported a role for SIRT3 
in oral cancer carcinogenesis. Sirtuin inhibitors, such as Sirtinol and Nicotinamide (NAM), that have been 
used to inhibit cell growth in several types of cancers, such as breast and lung cancers 24 also inhibited 
cell growth and proliferation, and induced apoptosis in several OSCC cell lines.   
Although some suggest a pro-apoptotic role for SIRT3 28-30, others suggest a pro-survival role 20-
22, 31. In addition, some reports suggest that SIRT3 is exclusively a mitochondrial protein 12-18, however, 
others find that SIRT3 can be found in the cytosol and nucleus under different cellular events 20, 32, 33. 
These reports underscore the complexity of sirtuins’ biological functions, which may differ according to 
their tissue of origin or cancer type. For example, SIRT1 functions in the neural system to promote neural 
cell survival and to protect against genomic toxicity 30, however, this may not be true in all cancer types. 
There is a discrepancy in the literature regarding the role of SIRT1 in cancer 7, 8, 24. After investigating the 
effect of SIRT1 in several cancer types, Stunkel et al. 34 concluded that SIRT1’s function in cancer is cell-
context dependant, and the role of SIRT1 can be independent of its deacetylase function. This cell 
specificity may also be true for SIRT3. When SIRT3 is overexpressed in cardiomyocytes, it increases 
stress resistance and plays a protective role against cell death and apoptosis 20. SIRT3 also seems to play a 
protective role against cardiac hypertrophy and heart failure 35.Furthermore, SIRT3 is overexpressed in 
breast cancer, and it was shown to modulate p53 activity, preventing growth arrest and senescence in 
bladder carcinoma cells 19, 22.  Because our present findings show that SIRT3 is overexpressed in OSCC 
tissues and cells (Fig. 2.1), we surmised that SIRT3 would also play a pro-survival role in oral cancer. 
Our current data indicate that SIRT3 levels are elevated in head and neck cancer and suppression 
of SIRT3 levels reduces several tumorigenic parameters in vitro and in vivo. In contrast, a recent study 
speculated on the role of SIRT3 in head and neck cancer by reviewing published gene array data from 
another source and indicated that SIRT3 levels are decreased in head and neck cancer 36. Those findings 
are contradictory to findings in the current report; however, it must be noted that those studies were 
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limited, since they were only gene array reviews and not a full functional assessment of SIRT3 in vitro 
and in vivo as in the present study.  
Downregulation of SIRT3 inhibited colony formation and induced apoptosis in OSCC cells. In 
addition, we investigated whether SIRT3 could modulate the sensitivity of OSCC cells to both IR and 
cisplatin treatment. We tested UM-SCC-1 and UM-SCC-17B cells, which are both highly resistant to 
radiation 37, 38, and the former is also resistant to cisplatin treatment (data not shown). Our data 
demonstrate that SIRT3 downregulation sensitized OSCC cells to both IR and cisplatin treatment, 
indicating that SIRT3 is important to the modulation of OSCC induced-resistance to both treatments. 
Thus, targeting SIRT3 to induce OSCC cell cytotoxicity in patients that have high SIRT3 expressing 
tumors could be advantageous, since lower doses of treatment would be required. Furthermore, SIRT3 
could serve as an adjunctive target to improve the efficacy and decrease the side effects of conventional 
treatments. In addition, despite SIRT3-deficient mice showing hyperacetylation of mitochondrial proteins, 
they are surprisingly healthy with normal bone mineral density and an unremarkable phenotype compared 
to SIRT3-wildtype mice 18. This suggests that targeting SIRT3 in oral cancer may be less toxic to normal 
cells versus cancer cells. Parenthetically, gene deletions of other sirtuins produce more aggressive and 
lethal phenotypes 39, 40.   
To further demonstrate the important role of SIRT3 in OSCC carcinogenesis, we used an in vivo 
murine floor-of-mouth model that mimics human OSCC 23, 27. This model has the advantage that tumors 
injected into the floor-of-mouth behave like human head and neck SCC, growing in the same 
environment, growing aggressively and invading surrounding tissues. It is noteworthy that our data 
indicate that tumor cells with low levels of SIRT3 grow slower, produce smaller tumor, and have less 
tumor volume compared with controls (Fig. 2.3 and Table 2.1). These findings support the in vitro data 
and indicate that SIRT3 plays an important role in oral cancer carcinogenesis in vivo.  
In summary, our findings reveal a novel role for SIRT3 in oral cancer carcinogenesis as a 
modulator of cell proliferation and survival, supported by in vitro and in vivo data. This implicates SIRT3 
as a new potential therapeutic target for treating oral cancer.  
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Figure 2.1: SIRT3 is overexpressed in oral squamous cell carcinoma. (A) Immunoblots reveal the levels of 
sirtuins (SIRT1-7) in OSCC cell lines (HSC-3, UM-SCC-1 and UM-SCC-17B), and in normal human oral 
keratinocytes (K). β-Actin served as loading control. (B) These representative samples show (top) SIRT3 expression 
levels in OSCC (tongue), and (bottom) in normal tissues. Immunoglobulin G (IgG) served as negative control. Scale 
bars = 200 µm for low-magnifications photomicrographs (left column); 50 µm for high-magnifications 
photomicrographs (middle and right columns) (C) These charts illustrate the percentage of normal and OSCC tissue 
specimens that expressed SIRT3 (top) in all samples and (bottom) in tongue samples, as determined by 
immunohistochemical staining. Note that SIRT3 staining intensities were designated as LOW (L) or HIGH (H) from 
Table 2.1. 
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Figure 2.2: The sirtuin inhibitors, sirtinol and nicotinamide (NAM) inhibit cell growth and proliferation, and 
induce apoptosis. (A) Shown are (top) phase-contrast images, and (bottom) histograms that reveal the morphology 
of cell growth and cell proliferation (%) of HSC-3, UM-SCC-1 and UM-SCC-17B oral squamous cell carcinoma 
(OSCC) cell lines after treatment with sirtuin inhibitors, sirtinol (50 µM), and nicotinamide (NAM, 40 mM) for 16 
and 24 h, respectively (Original magnification x100). (B) Cell death-detection ELISA assays were used to measure  
DNA fragmentation in cells after treatment with (top) sirtinol and (bottom) NAM as indicated. ** p≤ 0.01;  *** p≤ 
0.001; OD, optical density.    
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Figure 2.3: Sirtuin-3 (SIRT3) downregulation inhibits cell growth and proliferation and promotes apoptosis 
in oral squamous cell carcinoma (OSCC) cells. (A) (top) Immunoblots reveal the transfection efficiency of SIRT3 
in the UM-SCC-1 and UM-SCC17B OSCC cell lines at 36 hours after transfection with SIRT3 small interfering 
RNA (siSIRT3) or non-targeting control (siControl) (150 nM). β-Actin served as loading control. (middle) Cells 
were transfected as indicated and were cultured for one week, then stained with crystal violet and photographed. 
(bottom) Numbers of colonies are presented as the percentage of colonies obtained relative to controls. (B) Cell 
death- detection ELISA assays were used to measure DNA fragmentation in the cells after transfection. ** p≤ 0.01;  
*** p≤ 0.001; OD, optical density.  
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Figure 2.4: Sirtuin-3 (SIRT3) downregulation enhances the sensitivity of oral squamous cell carcinoma 
(OSCC) to radiation and cisplatin-induced cytotoxicity. (A) OSCC cells (UM-SCC-1 and UM-SCC-17B) were 
either untransfected or transfected with small interfering SIRT3 (siSIRT3) (150 nM) and were treated with (A) 
ionizing radiation (2.5 Gy) or (B) cisplatin (20 µM) for  24 h, and cytotoxicity was determined by the QUANT Cell 
Proliferation Assay Kit (Invitrogen) ** p≤ 0.01;  *** p≤ 0.001. 
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Figure 2.5: Sirtuin-3 (SIRT3) downregulation reduces oral squamous cell carcinoma (OSCC) tumor burden 
in vivo. (A) These immunoblots show SIRT3 expression levels in 4 clones from UM-SCC-17B cell lines where 
stably transduced with scrambled-short hairpin RNA (Scr-shRNA) or SIRT3-shRNA after 10 days of selection using 
Puromycin. β-Actin served as loading control. (B) Mice were injected with OSCC cells that stably Scr-shRNA or 
SIRT3-shRNA. Images show (top) the superficial growth of tumors in the head and neck region of the mice, 
(middle) dissected tumors in situ, and (bottom) dissected and isolated tumors for the 2 groups.  
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Figure 2.S1: The expression levels of SIRT7 in OSCCs. (A) Representative samples showing SIRT7 expression 
levels in OSCC (tongue) (top), and normal tissues (bottom). IgG served as negative control. (B) Percentage of 
normal and OSCC tissue specimens expressing SIRT7 in general (top) and in tongue (bottom), as determined by 
immunohistochemical staining. Note that SIRT7 staining intensity was designated as category Low (L) or HIGH (H) 
from supplementary Table 2.S1 data. (Scale bar represents 200 and 50 µm in low and high magnifications, 
respectively). 
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Table 2.1: Correlation of SIRT3 expression and clinicopathological  
variables in normal and OSCC tissues 
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Statistical analysis: Chi-square test; *significant difference p≤ 0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 No. of 
tissue 
specimens  
               SIRT3 staining intensity 
               No. of tissue specimens  
              (%) 
P value 
  
             Low High 
 
Normal 10   8 (80) 2 (20)  
Tumor 42    21 (50) 21 (50) Normal   vs 
Tumor 0.05* 
 
Normal  
 
10  
  
Tongue 7    6 (86)   1 (14)  
Tumor  42    
Tongue  26    10 (39) 16 (61) Normal 
Tongue 
vs 
Tumor 
Tongue  
0.04* 
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Table 2.2: Summary of tumor volume in mice injected with UM-SCC-17B cells 
stably expressing Scrambled-shRNA or SIRT3-shRNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistical analysis: independent t-test with unequal 
variances; ***significant difference p≤ 0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                    Scrambled-shRNA                SIRT3-shRNA 
         Animal               Tumor Volume (mm3)       Tumor Volume (mm3) 
 
1 
 
190.8 
 
 
21.1 
 
2 186.9 
 
35.75 
 
3 100.7 
 
32.8 
 
4 165.1 
 
20.1 
 
5 124.62 
 
26 
 
6 92.23 
 
28.5 
 
7 71.3 
 
37.4 
 
8 64.4 
 
40.63 
 
9 64 
 
15.3 
 
10 63.2 
 
11.9 
 
Mean 
Volume 
 
112.325 
 
   26.948*** 
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Table 2.S1: Correlation of SIRT7 expression and clinicopathological  
variablesin normal and oral SCC tissues 
 
 
 No. of 
tissue 
specimens 
               SIRT7 staining intensity 
               No. of tissue specimens 
               (%) 
 P value  
  
 Low High  
Normal 10   6 (60) 4 (40) 
 
Tumor 42  20 (48) 22 (52) Normal   vs 
Tumor  
p≤  0.8! 
 
Normal  
 
10 
  
Tongue 7  4(58) 3 (42) 
 
 
Tumor  
 
42 
  
 
Tongue 
 
 26  
 
 
 
12 (46) 
 
14 (54) 
 
Normal 
Tongue  
 vs  
Tumor 
Tongue  
p≤  .2!!
 
Statistical analysis: Chi-square test; *significant difference  p≤ 0.05!
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CHAPTER III 
 
RECEPTOR INTERACTING PROTEIN (RIP) AND SIRTUIN-3 (SIRT3) ARE ON OPPOSITE 
SIDES OF ANOIKIS AND TUMORIGENESIS 
 
ABSTRACT 
BACKGROUND: Regulating crosstalk between anoikis and survival signaling pathways is crucial to 
regulating tissue processes and mitigating diseases like cancer. Previously, we showed that anoikis 
activates a CD95/Fas-mediated signaling pathway regulated by receptor-interacting protein (RIP), a 
kinase that shuttles between Fas-mediated cell death and integrin/FAK-mediated survival pathways. Since 
sirtuin-3 (SIRT3), an NAD-dependent deacetylase, is known to regulate cell survival, metabolism, and 
tumorigenesis, we hypothesized that SIRT3 might engage in crosstalk with Fas/RIP/integrin/FAK 
survival-death pathways in cancer cell systems. METHODS: Using immunohistochemical staining, 
immunoblotting, human tissue microarrays, and overexpression and suppression approaches in vitro and 
in vivo we examined the roles of RIP and SIRT3 in oral squamous cell carcinoma (OSCC) anoikis 
resistance and tumorigenesis. RESULTS: RIP and SIRT3 have an opposite expression profile in OSCC 
cells and tissues. Stable suppression of RIP enhances SIRT3 levels, whereas, stable suppression of SIRT3 
does not impact RIP levels in OSCC cells. As OSCC cells become anoikis-resistant they form 
multicellular aggregates or oraspheres in suspension conditions, and their expression of SIRT3 increases 
as their RIP expression decreases. Also, anoikis-resistant OSCC cells with higher SIRT3 and low RIP 
expression induce an increased tumor burden and incidence in mice unlike their adherent OSCC cell 
counterparts. Furthermore, stable suppression of SIRT3 inhibits anoikis resistance and reduces tumor 
incidence. CONCLUSION: RIP is a likely upstream negative regulator of SIRT3 in anoikis resistance, 
and an anoikis-resistant orasphere phenotype defined by higher SIRT3 and low RIP expression 
contributes to a more aggressive phenotype in OSCC development.  
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Introduction 
Anoikis—apoptotic cell death triggered by loss of extracellular matrix (ECM) contacts— is 
dysregulated in many chronic debilitating and fatal diseases. Cancer cells evade apoptosis and possess 
self-sufficiency in growth signals; two important hallmarks of cancer cells1. Thus, cancer cells can evade 
apoptosis by escaping anoikis and becoming anoikis resistant. Anoikis-resistance or anchorage-
independent growth contributes to cancer development and progression2-5. Although smoking, alcohol 
consumption, and HPV are risk factors for oral cancer, other factors contributing to tumorigenicity are 
poorly studied. One such factor, anoikis-resistance induces more aggressive tumors in oral squamous cell 
carcinoma (OSCC)6-8.  
Oral cancer is one of the leading causes of death worldwide, and oral squamous cell carcinoma 
(OSCC) accounts for more than 90% of oral malignancies9, yet survival rates for oral cancer have not 
improved in decades. These disheartening statistics underscore the need to examine its pathogenesis and 
to identify novel biomarkers and modes of therapy.  
We recently showed that receptor interacting protein (RIP), shuttles between CD95/Fas death and 
FAK survival signaling pathways to mediate anoikis in OSCC cells10. Hence, under anoikis conditions, 
FAK and RIP dissociate, leading to the association of RIP with Fas and the formation of the death 
inducing signaling complex, thus enhancing apoptosis. These findings support the development of 
therapeutics that can target RIP as a switch to control cell death or survival pathways to ultimately 
regulate normal tissue processes and tumorigenesis in cancer patients.  
Sirtuins (SIRT1-7), the mammalian homologues of the Sir2 gene in yeast, have an emerging role 
in regulating cellular processes and functions including cell survival, apoptosis, oxidative stress, 
development, metabolism, and aging11, 12. We recently reported that SIRT3, one of the mitochondrial 
sirtuins13-15, is overexpressed in OSCC cells and tissues compared to normal, and that downregulation of 
SIRT3 in OSCC cells inhibited cell growth and proliferation, and increased their sensitivity to both 
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radiation and chemotherapy treatments14. In addition, by using a floor-of-mouth oral cancer murine model 
that mimics human OSCC16, 17, we showed that SIRT3 downregulation reduced tumor burden in vivo, 
implicating a prosurvival role for SIRT3 in oral cancer tumorigenesis14. However, the role of SIRT3 in 
anoikis resistance has not been investigated. Here, we reported for the first time a role for SIRT3 in 
mediating anoikis-resistance in oral cancer and its potential cross-talk with RIP.  
 
Materials and Methods 
Cell lines and culture 
 Human OSCC cells (HSC-3) was kindly provided by Randy Kramer (University of California, San 
Francisco, CA). The human OSCC cells UM-SCC-14A was a gift from Tom Carey (University of 
Michigan, Ann Arbor, MI). The poorly differentiated aggressive tongue SCC cell line OSCC-3 was gift 
from Mark Lingen (University of Chicago, Chicago). OSCC cells were maintained in Dulbecco’s 
modified Eagle’s medium containing 10% fetal bovine serum, 1% penicillin, and 1% streptomycin. 
Primary human oral keratinocytes (ScienCell, Carlsbad, CA) were maintained in oral keratinocyte 
medium (OKM), (ScienCell, Carlsbad, CA). RIP-/- mouse embryonic fibroblasts (MEFs) were kindly 
provided by Philip Leder and Michelle Kellinger (Harvard Medical School, Boston, MA). 
 
Tissue microarrays 
 Immunohistochemical analyses were performed to determine the expression of SIRT3 and RIP in human 
OSCC tissues using OSCC tissue microarrays (OR601 and HN241; US Biomax, Inc., Rockville, MD) and 
the Histostatin Kit (95-6143; Zymed Laboratories, South San Francisco, CA) according to the 
manufacturer’s instructions. Antibodies to SIRT3 (AP6242a) and RIP (610459) were from ABGENT 
(San Diego, CA), and Millipore (Billerica, MA), respectively. Staining intensities were graded in a 
blinded manner as either low (L) or high (H) by a pathologist. 
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Transient transfection 
 HSC-3 cells at 60–70% confluency were transiently transfected with small interfering RNA (siRNA) (25 
or 50 nM) against RIP or with a nontargeting control siRNA (Santa Cruz Biotechnology, Santa Cruz, CA) 
in serum-free medium that contained Lipofectamine Plus (Invitrogen, Carlsbad, CA). RIP-/- mouse 
embryonic fibroblasts were transiently transfected with myc-tagged wild-type RIP or control vector as 
described previously10. Transfection efficiency was assessed by Western blot analysis. 
 
Stable transfection 
HSC-3 and UM-SCC-14A cells were transduced with either RIP-shRNA (sc-44326-V), SIRT3-shRNA 
(sc61555-vs) or scrambled-shRNA (sc-108084) (Santa Cruz Biotechnology) lentiviral particles in 0.5 mL 
of serum-free media, then selected in 10 µg/ml puromycin (sc-108071; Santa Cruz Biotechnology) for an 
additional 10 days. Surviving cell colonies were picked and propagated before testing for RIP or SIRT3 
expression using Western blot analysis.  
 
Immunoblot analysis 
 To evaluate the expression levels of RIP and SIRT3, cells were treated as described above or in figure 
legends, washed once with phosphate-buffered saline, lysed in RIPA buffer (R0278, Sigma) that 
contained 1% protease inhibitor cocktail (P8340, Sigma), then kept on ice for 30 minutes. Lysates were 
adjusted for protein concentration with the BCA protein assay kit (Bio-Rad, Hercules, CA). Western blot 
analyses was performed with various primary antibodies and horseradish peroxidase-conjugated antirabbit 
or antimouse IgG antibodies, and blots were developed with the ECL-Plus detection system (Pierce, 
Rockford, Ill). Antibodies for RIP (610459) and SIRT3 (2627) were from Millipore (Billerica, MA) and 
Cell Signaling Technology (Beverly, MA), respectively. To demonstrate equal protein loading, 
membranes were stripped and reprobed with an anti-β-actin antibody (sc-1615; Santa Cruz 
Biotechnology). 
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Anoikis-resistant and control adherent OSCC cells  
Anoikis-resistant oraspheres (UM-SCC-14A and HSC-3) and adherent (UM-SCC-14A and HSC-3) 
OSCC cells were prepared as previously reported4. These OSCC cell lines were selected because they 
represent the extremes of RIP and SIRT3 expression among OSCC cell lines examined. These OSCC 
cells were developed by maintaining cells under suspension conditions on poly- HEMA coated plates (7.5 
mg/ml in 95% ethanol, Sigma) for 6 days, where they survive anchorage withdrawal by forming 
multicellular aggregate oraspheres. Adherent control cells were maintained in culture medium as 
described previously.  
 
Immunodeficient mouse tumor model 
To examine the effects of anoikis-resistance and adherent OSCC cells in vivo, UM-SCC-14A and SIRT3 
suppressed UM-SCC-14A cells and controls were grown in anoikis resistant and adherent conditions as 
described above. Four-week-old athymic nude mice (NCr-nu/nu strain, NCI, Frederick, MD) were 
anesthetized by intraperitoneal injection with 100 mg/kg ketamine and 10 mg/kg xylazine. We used a 
murine floor-of-mouth model, which we previously optimized to produce 4-mm to 5-mm tumors, 
corresponding to a palpable tumor volume of 35-60 mm3, within approximately 2 to 4 weeks after 
injection of tumor cells14, 16. Anoikis-resistant and adherent control UM-SCC-14A cells were prepared to 
a final concentration of 1.0 x 106 /0.05 ml and injected submucosally into the floor of the mouth as 
described previously14.  Six weeks after injection, mice were euthanized, tumor volumes were measured 
by digital caliper using the formula a x a x b/2, where a is the smaller dimension. Tumor tissues were then 
harvested, rinsed in PBS, and fixed overnight in 10% buffered formalin. Tissues were paraffin-embedded, 
sectioned, and processed for routine histopathological assessment with hematoxylin and eosin staining 
and for SIRT3 and RIP immunostaining.  
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Apoptosis cell death detection by ELISA 
Apoptosis was measured in vitro by a DNA-fragmentation enzyme-linked immunosorbent assay 
(ELISA), according to the manufacturer’s instructions (Roche Diagnostics, Indianapolis, IN). 
 
Statistical Analysis  
In general, values are expressed as means ± SD. Intergroup differences were determined by two-way 
analysis of variance (ANOVA) and Scheffe's multiple-comparison test. Statistical significance was 
defined as * p ≤ 0.05. For tissue microarray analyse, McNemar’s test was used to compare the two 
proportions and are considered significantly different when P≤ .001. For the in vivo studies, independent t 
tests with unequal variances were used. All experiments were repeated at least 3 times. 
 
Results 
SIRT3 and RIP are oppositely expressed in oral squamous cell carcinoma in vivo 
We recently reported that SIRT3 is overexpressed in OSCC in vivo and in vitro compared to other sirtuins 
and its stable suppression reduces tumor burden in vivo, implicating SIRT3 as a prosurvival and tumor 
promoting factor14. In addition, we showed that RIP plays a critical role in OSCC cells by regulating 
anoikis through its shuttling between CD95/Fas death and FAK survival signaling pathways, thus 
demonstrating that RIP acts as a switch between life and death signals in OSCC cells10. Also, sirtuin-3 
(SIRT3) is known to regulate cell survival, metabolism, and tumorigenesis. Therefore, we hypothesized 
that SIRT3 might engage in crosstalk with RIP to regulate anoikis-resistance and tumorigenesis in OSCC 
cells. To test this hypothesis, we first evaluated the native expression levels of SIRT3 and RIP in serial 
sections of OSCC tissue microarrays (TMAs). Our data included 28 OSCC tongue samples in which 
SIRT3 and RIP expression were evaluated and assessed as low (L) or high (H) (Table 1). SIRT3 and RIP 
staining intensity data from Table 3.1 are illustrated in Figure 3.1B. We already knew that SIRT3 
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expression levels were elevated in human OSCC14, however the relative expression level of RIP in these 
same tissues was not known. Interestingly, we found that SIRT3 and RIP were oppositely expressed in 
OSCC tissues (Fig. 3.1A). In 86% of the samples where SIRT3 expression was high, 75% of them had 
low RIP expression (Fig. 3.1B; Table 3.1). Thus 64% (18/28) of the specimens showed an opposite 
expression pattern for SIRT3 and RIP (Fig. 3.1A and B, Table 3.1; p ≤ 0.05).  
SIRT3 and RIP are oppositely expressed in oral squamous cell carcinoma in vitro 
Similarly, when we examined several OSCC cells (HSC-3, OSCC-3, and UM-SCC-14A) for SIRT3 and 
RIP expression, we again found that SIRT3 expression was opposite to that of RIP expression in these 
cells (Fig. 3.2A). Primary oral keratinocytes also showed an opposite pattern of SIRT3 and RIP 
expression, however, these cells generally exhibited higher levels of RIP expression compared to SIRT3 
(Fig. 3.2A). These findings further suggested that RIP and SIRT3 participate in a crosstalk mechanism. 
To test this further, OSCC cell lines (HSC-3 and UM-SCC-14A) were selected for further experiments to 
determine whether RIP or SIRT3 regulate each other and to examine the hierarchy of this potential 
crosstalk. These OSCC cell lines were chosen because they represent the extremes of SIRT3 and RIP 
expression among OSCC cell lines examined. Transient suppression of RIP effectively increased SIRT3 
expression levels (Fig. 3.2B). However, stable suppression of SIRT3 failed to alter RIP expression levels 
(Fig. 3.2C). Furthermore, reconstitution of RIP in RIP null cells down-regulated SIRT3 expression (Fig. 
3.2D). This indicated that SIRT3 was responsive to changes in RIP levels but not the contrary, suggesting 
that RIP is a potential upstream regulator of SIRT3. 
Anoikis-resistant OSCC oraspheres express higher levels of SIRT3 and lower levels of RIP 
To examine the anoikis-resistant phenotype of OSCC cells, an orasphere culture assay was used to study 
the SIRT3 and RIP expression profile of OSCC cells in vitro. We specifically developed anoikis-resistant 
cells and their counterpart adherent controls (HSC-3 and UM-SCC-14A; as described previously). Our 
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data show that anoikis-resistant OSCC cells in oraspheres maintain cell survival and exhibit low levels of 
DNA fragmentation or apoptosis (Fig. 3.3A and B). In contrast, the single cell counterpart of suspension 
cultures undergoes apoptosis and exhibit high levels of DNA fragmentation (Fig. 3.3A and B). The 
adherent counterpart control cells, like the cells in oraspheres, also have low levels of DNA 
fragmentation. Interestingly, however, the oraspheres express higher levels of SIRT3 and lower levels of 
RIP compared to the adherent cells (Fig. 3.3C), suggesting that OSCC cells escape anoikis-mediated cell 
death in part by relying on SIRT3 survival signaling and suppression of RIP death signaling pathways.  
Anoikis-resistant orasphere-derived OSCC cells that express higher levels of SIRT3 and lower 
levels of RIP induce a greater tumor burden 
Furthermore, to investigate the in vivo relevance of our in vitro findings, we used a murine floor-of-mouth 
model that mimics human OSCC14, 16, 17. Mice were injected with anoikis-resistant orasphere-derived 
OSCC cells that express higher SIRT3 levels (UM-SCC-14A) or their adherent OSCC cell counterparts 
that express lower SIRT3 levels (Fig 3.4). Our data show that mice injected with anoikis-resistant 
orasphere-derived cells exhibit greater tumor burden compared to their adherent counterparts (Fig. 3.4A 
and Table 3.2). Not only did the mice injected with orasphere-derived cells develop significantly larger 
tumors (12 fold difference in size; p≤0.027), but they also developed more tumors (9/10), compared to 
(2/8) mice injected with adherent control cells (Table 3.2; p≤0.001) Histologic examination of tumors 
dissected from mice injected with orasphere-derived cells revealed a highly disorganized histologic 
pattern of invasive epithelial islands with keratin pearl formation, nuclear pleomorphism, 
hyperchromatism, and increased nuclear to cytoplasmic ratios compared to their control counterparts (Fig. 
3.4B). These “aggressive” tumors also revealed high levels of SIRT3 expression and low levels of RIP 
expression (Fig. 3.4B). In 80% of the samples where SIRT3 expression was high, 78% of them had low 
RIP expression (Fig. 3.4C). In contrast, the few tumors that emerged in mice injected with adherent 
control cells revealed a tendency towards regularly organized histologic pattern of epithelial islands and a 
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relatively lower level of SIRT3 expression (data not shown). These data support our in vitro findings and 
those of others6, 7  indicating that anoikis-resistant cells induce a greater tumor burden and a more 
aggressive phenotype in OSCC. In addition, these cells seem to rely, at least in part, on SIRT3 
upregulation and RIP downregulation to maintain their survival and aggressive phenotype. Thus, high 
SIRT3 and low RIP expression may impart resistance to anoikis-mediated cell death.  
SIRT3 upregulation and RIP downregulation regulate the fate of OSCC cells in anoikis conditions 
To further validate the importance of SIRT3 and RIP in regulating the fate of OSCC cells under 
suspension/anoikis conditions, stable cell clones of SIRT3-shRNA (Clone2) and scrambled-shRNA 
(Clone 1) were examined under adherent and suspension conditions. Our data show that under suspension 
conditions, cells expressing SIRT3-shRNA can no longer form oraspheres, maintain their survival, or 
escape anoikis, unlike cells expressing scrambled-shRNA (Fig. 3.5A), confirming the role of SIRT3 in 
anoikis resistance. In addition, cells in suspension conditions stably expressing SIRT3-shRNA 
(oraspheres and single cells) showed increased levels of RIP expression and higher levels of DNA 
fragmentation compared to cells expressing SIRT3-shRNA and grown in adherent conditions or cells 
expressing scrambled-shRNA and grown in adherent or suspension conditions (Fig. 3.5B and C). 
Furthermore, stable suppression of SIRT3 inhibits anoikis resistance and reduces tumor incidence in vivo 
(Fig. 3.5D). The higher RIP expression present in the cells transduced with SIRT3-shRNA in suspension 
conditions likely represents the single cell fraction present in this mixed culture system. Furthermore, RIP 
overexpression promotes anoikis10 and RIP suppression inhibits DNA fragmentation (Fig. 3.6). These 
data show that SIRT3 and RIP are at opposite ends of anoikis resistance in OSCC cells, and SIRT3 is 
required for escaping anoikis and for acquisition of an anoikis-resistant phenotype. Based on these 
findings, we propose a model for SIRT3’s role in regulating survival and anoikis resistance (Fig. 3.7). 
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Discussion 
Cancers that are prone to metastases possess an anoikis-resistant phenotype, thereby acquire a 
more aggressive behavior, resistance to treatment, and contributing to poor survival rates. This has been 
the case for several cancers, such as prostate, hepatic, and oral cancer6, 18, 19. Thus, understanding the 
molecular mechanisms underlying an anoikis-resistant phenotype will help identify new potential 
therapeutic targets to treat aggressive cancer.  
Our previous report that RIP can shuttle between survival and death signaling pathways under 
anoikis conditions in oral cancer10, demonstrates the important role of RIP in controlling the fate of 
OSCC cells under anoikis conditions. In addition, our recent finding that OSCC cells rely on SIRT3 to 
maintain their survival and aggressive behavior also suggests an important role for SIRT3 in OSCC 
tumorigenesis. Specifically, we found that SIRT3 downregulation decreased OSCC cell proliferation and 
survival, enhanced the sensitivity of OSCC radio- and chemo-resistant cells to both radio- and 
chemotherapeutic treatments, and reduced tumor burden in vivo14. Here, we show for the first time a link 
between anoikis-resistance and SIRT3 in oral cancer and its potential cross-talk with RIP, thus 
highlighting one important new mechanism by which SIRT3 can modulate OSCC progression.  
Our data show that SIRT3 and RIP are oppositely expressed in OSCC and that OSCC cells escape 
anoikis by forming multicellular aggregates or oraspheres to maintain their survival compared to single 
cells, which undergo anoikis-mediated cell death. Interestingly, OSCC cells seem to rely, at least in part, 
on altering their SIRT3 and RIP levels to escape anoikis. Furthermore, OSCC cells stably expressing 
downregulated levels of SIRT3 failed to form oraspheres, and thus experienced significantly more 
anoikis, suggesting a critical role for SIRT3 in regulating anoikis-resistance in OSCC cells. In agreement 
with our findings, lung adenocarcinoma cells form spheroids or aggregates that express E-cadherin and p-
Src to maintain their survival under suspension conditions. Thus, Src was found to be an essential 
regulator in the development of anoikis-resistance in lung adenocarcinomas20. Also, mammosphere 
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cultures of breast cancer cells from pleural effusions are tumorigenic and induce tumors in SCID mice5. 
Furthermore, a recent report demonstrate that ovarian cancer spheroids use integrin- and talin-dependent 
activation of myosin and traction forces to promote displacement of  mesothelial cells from underneath a 
tumor cell spheroid22.  In summary, multiple studies support the concept that spheroid formation promotes 
cancer cell survival and tumorigenesis. 
Limited studies have examined the role of anoikis-resistance in OSCC progression and aggressive 
behavior using in vivo models. One study used a tongue oral cancer mouse model to show that anoikis-
resistant OSCC cells are more aggressive than their anoikis-sensitive counterparts, and mice injected with 
these cells have shorter survival rates (17 days versus 30 days) compared to mice injected with anoikis-
sensitive OSCC cells6. In our current study, we used a different in vivo model, a murine floor-of-mouth 
model that mimics human OSCC16, 17, and showed that anoikis-resistant OSCC cells, which express 
increased levels SIRT3 and decreased levels of RIP, exhibit greater tumor burden compared to their 
adherent OSCC counterparts. These data further support our previous in vivo findings, whereby OSCC 
cells with stably suppressed levels of SIRT3 injected in the same murine floor-of-mouth model exhibited 
reduced tumor burden compared to controls14. Thus, our current data support that SIRT3 and RIP are 
oppositely expressed in OSCC anoikis-resistant cells and this enables these cells to escape anoikis and 
take on a more aggressive phenotype. Since this short 6-week floor-of-mouth model is not optimal for 
examination of oral metastases, other animal models of metastases are needed to examine this process 
specifically in future studies.  
RIP can localize to the cytoplasm or the mitochondria. In the mitochondria, RIP inhibits 
ADP/ATP exchange via modulating adenine nucleotide translocate (ANT). This modulation results in the 
loss of ANT and cyclophilin-D interactions, reduction in ATP levels, and induction of cell death21, and 
implicates RIP in mitochondrial-mediated cell death. In addition, although there is debate about the 
subcellular localization of SIRT3, most reports support a mitochondrial localization for SIRT322-30. Our 
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data show that SIRT3 and RIP are oppositely expressed in OSCC and they regulate anoikis-resistance in 
OSCC cells. Since SIRT3, a mitochondrial sirtuin, can localize to the mitochondrial matrix, and RIP can 
be localized in the cytoplasm31, 32, this suggests that these two molecules may interact indirectly via other 
molecules. However, additional studies indicate that RIP is also identified in the mitochondria, and 
therefore can potentially interact directly with SIRT321, 33. Furthermore, some evidence suggests that RIP 
is critical for regulating ROS mechanisms34, 35 and it is well known that SIRT3 is functionally also 
important in ROS regulation15, 36, 37. Therefore, RIP and SIRT3 may be functionally related via ROS 
regulation pathways in the context of anoikis resistance. However, whether this regulation is mediated via 
direct or indirect interactions between SIRT3 and RIP is an area that is currently under investigation by 
our group. 
There is also a debate in the literature regarding the role of SIRT3 in cancer15. Although, some 
reports support a prosurvival role for SIRT3 in cancer14, 15, 38-41, others support a tumor suppressor role for 
SIRT342-44. Our previous and current studies demonstrate that SIRT3 plays a prosurvival role in oral 
cancer, that SIRT3 assists in chemo- and radioresistance, and that by promoting anoikis-resistance, SIRT3 
mediates a more aggressive tumorigenic phenotype.   
In summary, our studies reveal for the first time a novel role for SIRT3 as a modulator of anoikis-
resistance in oral cancer via potential cross-talk with RIP. This work further enriches our understanding of 
SIRT3’s role in the regulation of oral cancer tumorigenesis and implicates SIRT3 as new potential 
therapeutic target to treat oral cancer.  
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Figure 3.1: RIP expression shows an opposite relationship to SIRT3 expression in oral squamous 
cell carcinoma (OSCC). (A) RIP and SIRT3 expression in OSCC TMA specimens are illustrated. Scale 
bars, 200 µm for low-magnification photographs (top) and 50 µm for high-magnification 
photomicrographs (bottom). (B) Percentage of OSCC tissue specimens expressing RIP and SIRT3 in 
tongue serial sections, determined by immunohistochemical staining. Staining intensity was graded as 
High or Low. McNemar’s test was used to compare the two proportions and are significantly different, P≤ 
.001.  
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Figure 3.2: RIP may be an upstream negative regulator of SIRT3. (A) Immunoblots show RIP and 
SIRT3 levels in normal human keratinocytes and oral squamous cell carcinoma cells (OSCC) plated for 
one day. β-actin served as loading control.  (B) Immunoblots show RIP and SIRT3 levels after 
transfection with control siRNA or RIP siRNA (25 or 50 nM) in HSC-3 cells for 30 h (C) Immunoblots 
show SIRT3 and RIP levels after stable SIRT3 suppression using lentiviral particles (scrambled controls 
or SIRT3-shRNA) in UM-SCC-14A cells.  (D). Immunoblots show RIP and SIRT3 levels after 
transfection with wild-type myc-RIP in RIP null cells (RIP-/-) for 30 h. 
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Figure 3.3: As OSCC cells become anoikis resistant their SIRT3 expression increases as their RIP 
expression decreases. (A) Phase contrast images of OSCC cells (HSC-3 and UM-SCC-14A) cultured 
under adherent or suspension conditions for 6 days and orasphere and single cells were separated for 
analysis. (B) Fold change of DNA fragmentation in adherent, orasphere and single cells. (C) Immunoblots 
showing RIP and SIRT3 expression in adherent and orasphere.  
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Figure 3.4: Anoikis resistant OSCC cells induce greater tumor burden in mice. (A) Images of tumor-
bearing mice 6 weeks after injection with adherent or orasphere/anoikis resistant UM-SCC-14A cells. Top 
panels show superficial tumors and lower panels show dissected tumor. (B) Representative orasphere 
derived tumor section stained with H&E (left) and immnostained with antibodies for RIP (middle) and 
SIRT3. (C) Percentage of tissue specimens expressing RIP and SIRT3 in orasphere derived tumor 
sections, determined by immunohistochemical staining. Staining intensity was graded as High or Low. 
McNemar’s test was used to compare the two proportions and are significantly different, P≤ .001.  
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Figure 3.5: SIRT3 suppression blocks orasphere formation, inhibits anoikis resistance, and reduces 
tumor incidence in vivo. (A) Phase contrast images of UM-SCC-14A cells transduced with scrambled 
shRNA (Scr-shRNA) or SIRT3 shRNA (viral transduction and puromycin selection for 10 days) then 
cultured under adherent or suspension (oraspheres plus single cells) conditions for 6 days. (B) 
Immunoblots show RIP and SIRT3 levels in scrambled controls or SIRT3 suppressed UM-SCC-14A cells 
cultured under adherent or suspension (oraspheres/anoikis-resistant) conditions for 6 days. (C) Fold 
change in DNA fragmentation in adherent or suspension (orasphers plus single cells) conditions for 6 
days. (D) Percentage of tumor incidence in nude mice injected with SIRT3 suppressed UM-SCC-14A 
cells (SIRT3-shRNA) or scrambled controls (Scr-shRNA) from adherent or suspension (oraspheres plus 
single cells) conditions after 6 weeks. Tumor incidence is shown relative to the number of animals in each 
group.  
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Figure 3.6: RIP suppression inhibits DNA fragmentation. (A) Immunoblots show RIP and SIRT3 
levels after stable RIP suppression using lentiviral particles (scrambled controls or RIP-shRNA). (B) Fold 
change in DNA fragmentation in adherent or suspension (oraspheres plus single cells) conditions for 6 
days.  
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Figure 3.7: Working model of anoikis resistance. Anoikis-resistant cells form multicellular aggregates 
(oraspheres) that express higher SIRT3 levels as their RIP expression decreases thereby promoting their 
survival and more aggressive phenotype in OSCC development and progression. 
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     Table 3.1. The expression profile of RIP and SIRT3 from 28 
     different tongue TMAs samples 
    
     Sample       Section        Sex             Age          RIP        SIRT3 
     number       number  
   
1 
 
A1 M 57 L H 
2 A6 F 35 H H 
3 A7 M 78 L H 
4 A9 F 39 L L 
5 A10 F 46 L H 
6 B3 F 57 L H 
7 B4 F 36 L H 
8 B8 F 47 H H 
9 B9 F 63 L L 
10 B10 M 56 L L 
11 C2 F 55 L H 
12 C3 M 76 L H 
13 C4 F 50 L H 
14 C6 M 55 H H 
15 C9 M 60 L H 
16 D1 M 64 L H 
17 D2 F 52 L H 
18 D3 F 50 L H 
19 D4 F 46 L H 
20 D5 F 45 L H 
21 D6 M 35 L H 
22 D7 F 46 H H 
23 D8 F 48 H L 
24 E3 M 60 H H 
25 E4 M 37 L H 
26 E6 M 60 L H 
27 E8 M 60 H H 
28 E10 M 73 L H 
  
 
 
 
 
Staining intensity was graded as Low (L) or High (H) 
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   Table 3.2. Tumor volumes for mice injected  
   with UM-SCC-14A 
                      
                         Adherent          Orasphere/ 
                                              Anoikis resistant 
     
     Animal          Tumor                   Tumor  
                          Volume                 Volume 
                          (mm3)                    (mm3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 31.20 
                                                                    
518.9 
2 19.64 444.36 
3 No tumor 22.86 
4 No tumor 864 
5 No tumor 243.3 
6 No tumor 252 
7 No tumor 215.66 
8 No tumor 138.16 
9 _ 83.49 
10 _ No tumor 
 
  
   
Mean  
Volume       25.42*                      311.84* 
Statistical analysis: Independent t-test with 
unequal variances p≤0.027 
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CHAPTER IV 
 
 
A NOVEL SIRTUIN-3 (SIRT3) INHIBITOR, LC-0296, INHIBITS CELL 
PROLIFERATION AND SURVIVAL, AND PROMOTES APOPTOSIS IN HEAD AND 
NECK CANCER CELLS 
 
ABSTRACT 
!
The poor survival rate of head and neck squamous cell carcinoma (HNSCC), which stands at 
approximately 50%, underscores the need to explore new areas of research and develop new 
therapeutic drugs and approaches that can help improve the survival rate of head and neck cancer 
patients. Sirtuins (SIRT1-7) have emerged as important modulators of different tumorigenic 
processes, thus implicating sirtuin modifiers as new potential therapeutic approaches to treat 
cancer. In this report, we show for the fist time a novel role for a SIRT3 inhibitor, LC-0296, in 
inhibiting cell survival and proliferation, and promoting apoptosis in HNSCC cells, but not in 
normal human oral keratinocytes. This inhibitory effect is mediated, at least in part, via 
modulating reactive oxygen species (ROS) levels. In addition, LC-0296 works synergistically to 
increase the sensitivity of HNSCC cells to both radiation and cisplatin treatments. In summary, 
the development of novel SIRT3 inhibitors, such as LC-0296, might enable the development of 
new targeted therapies to treat and improve the survival rate of head and neck cancer patients.   
 
Introduction 
       Head and neck squamous cell carcinoma of (HNSCC) is the type of cancer that originates 
from the oral and nasal cavities, sinuses, lips, salivary glands, throat, or larynx. Oral squamous 
cell carcinoma (OSCC) represents the majority of HNSCC and it is the eighth most common 
cancer worldwide [1]. In some countries, including India and other south-central Asian countries, 
oral cancer is among the most commonly occurring cancers. Although other cancers such as 
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breast, prostate and colon cancers are more prevalent than oral cancer, the 5-year survival rate of 
this disease is poor, averaging 50% [1]. Despite the advancements in therapeutic approaches to 
treat this devastating disease, oral cancer still holds one of the worse survival rates compared to 
other cancer types worldwide. In the U.S., one person is estimated to die every hour from oral 
cancer [1], whereas in Canada, three people die from this disease hourly [2]. This underscores the 
urgent need to explore new areas of research and develop new therapeutic drugs and approaches 
that can help improve the survival rate of head and neck cancer patients.  
       Sirtuins (SIRT1-7) have emerged as important modulators of different tumorigenic processes. 
Sirtuins control cancer cell proliferation and survival, cell cycle progression, apoptosis, 
angiogenesis, and metabolism [3,4,5,6]. Therefore, sirtuins have been implicated as novel 
potential therapeutic targets to treat cancer [7]. However, the role of several sirtuins, specifically 
SIRT1 and SIRT3, in cancer tumorigenesis has been controversial [8,9,10]. Thus, expanding the 
study of sirtuins in this new area of research will help advance the field and help us to better 
understand the mechanisms by which sirtuins can regulate different cancer processes.  
       We were the first to demonstrate a novel role for SIRT3 in oral cancer tumorigenesis in vitro 
and in vivo [11]. We previously reported that of all the seven sirtuin family members, SIRT3 is 
overexpressed in OSCC compared to normal oral tissues, and SIRT3 downregulation enhances 
the sensitivity of OSCC cells to both radiation and chemotherapeutic drugs. In addition, SIRT3 
downregulation inhibits OSCC cell growth and proliferation in vitro, and reduces tumor burden in 
vivo [11]. Furthermore, we found that SIRT3 and receptor interacting protein (RIP), a 
proapoptotic protein, are oppositely expressed in OSCC human tumor specimens. In addition, 
OSCC cells escape anoikis, apoptotic cell death triggered by loss of extracellular matrix (ECM) 
contacts, by forming multicellular aggregates or oraspheres to maintain their survival, unlike 
single cells, which undergo anoikis-mediated cell death (Y. Kapila’s group, unpublished data 
under revision). Thus, OSCC oraspheres become anoikis-resistant, a condition defined by a 
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higher SIRT3 and low RIP expression. These anoikis-resistant OSCC cells also induce an 
increased tumor burden and incidence in mice unlike their adherent OSCC cell counterparts. 
Furthermore, stable suppression of SIRT3 inhibits anoikis-resistance and reduces tumor incidence 
(Y. Kapila’s group, unpublished data under revision). These findings suggest that SIRT3 may be 
a new potential therapeutic target to treat head and neck cancer patients.  
       In this regard, we believe that discovering new drugs that specifically target SIRT3 could 
enhance the treatment of HNSCC cancer and this would be of a great interest for potentially 
improving the survival rate of head and neck cancer patients. In this study, we report for the first 
time the use of a novel SIRT3 chemical inhibitor, LC-0296, that retards OSCC cell proliferation 
and survival, and promotes apoptosis through the modulation of reactive oxygen species (ROS). 
In addition, inhibiting SIRT3 enzymatic activity with this inhibitor increases the sensitivity of 
HNSCC cells to radiation and chemotherapeutic treatments. To our knowledge, our report is the 
first to show a promising new specific SIRT3 chemical inhibitor that can form the basis for future 
therapeutics for head and neck cancer patients.  
 
Materials and Methods 
Brief description of chemical synthesis and reaction conditions. The synthesis of compound 
LC-0296 (6) was straightforward and is depicted in Figure 4.S1. Commercially available 4-nitro-
1H-indole (1) was alkylated to give compound 3, whose nitro group was reduced to the 
corresponding amine in compound 4 in excellent yields. The methyl ester group in compound 4 
was converted into a primary amide with methanolic ammonia. The resulting compound 5 was 
coupled with L-glutamate derived Z-Glu-OMe in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt) to 
yield LC-0296 in good yields (Figure 4.1). More detailed information about the chemical 
synthesis can be found in supplementary methods (Figure 4.S1 and Methods 4.S1).  
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Biochemical in vitro assays. The biochemical assays against human SIRT1-3 were performed by 
the Reaction Biology Incorporation (RBC) (Malvern, PA, USA, 
http://www.reactionbiology.com). Full length human SIRT1 (GenBank Accession No. 
NM_012238, MW = 82 kDa), full length human SIRT2 (GenBank Accession No. NM_012237, 
MW = 43 kDa), and catalytically active human SIRT3 (GenBank Accession No. NM_012239, 
amino acids 102-399, MW = 32.7 kDa) were expressed in E. coli and purified. All assays were 
performed using a fluorogenic 7-amino-4-methylcoumarin (AMC)-labeled substrate (RHKK(Ac)-
AMC), which is based on residues 379–382 of p53. The assays were performed in a buffer of 50 
mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2 and 1 mg/ml BSA, which was 
added before use. The testing involved a two-step reaction. First, 50 µM AMC-labeled substrate 
with an acetylated lysine side chain was incubated with 91 nM SIRT1 for 2 hours at 30 ºC to 
produce the deacetylated substrate. The concentrations of SIRT2 and SIRT3 were 233 and 917 
nM, respectively. Second, the deacetylated substrate was digested by a mixture of developer to 
release AMC that was detected at 360/460 Ex/Em. The intensity of fluorescence was proportional 
to the amount of the deacetylated substrate. Each compound was dissolved in DMSO, 
sequentially diluted, and used for testing. IC50 values were calculated from the resulting sigmoidal 
dose-response curves. Suramin was used as a reference compound for SIRT1 as well as SIRT2, 
and nicotinamide for SIRT3. 
 
Cell lines and culture. Human HNSCC cell lines, UM-SCC-1 and UM-SCC-17B, originated 
from the floor of the mouth and larynx, respectively, and were from Tom Carey (University of 
Michigan). HNSCC cells were maintained in DMEM (Gibco) supplemented with 10% fetal 
bovine serum, 1% penicillin/streptomycin. Primary normal human oral keratinocytes (Cat# 2610, 
ScienCell) were maintained in human oral keratinocytes medium (#2611, ScienCell).  
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Cell viability and colony formation assays. To determine the effect of the SIRT3 inhibitor, LC-
0296, on cell viability we used the QUANT Cell Proliferation Assay Kit according to 
manufacturer’s instructions (Invitrogen), under the conditions described in figure legends. For 
colony formation assays, HNSCC cells and normal human oral keratinocytes were treated and 
cultured for one week. Colonies were fixed with methanol, and then stained with 0.5% crystal 
violet. Colonies containing greater than 50 cells were counted.  
 
Apoptosis cell death detection assay (ELISA). To measure apoptosis in vitro, a DNA 
fragmentation enzyme-linked immunosorbent assay (ELISA) was used according to 
manufacturer’s instructions (Roche Diagnostics, Indianapolis, IN, USA). 
 
Combination Index (CI).  To determine synergistic or additive effects of the drug combinations, 
a CI was used following the procedure developed by Fischel et al. [12], with the equation adapted 
from the method developed previously by Chou and Talalay [13]: 
                   R = 
Survival (LC-0296 + IR or CDDP) 
Survival (LC-0296 alone) X (IR or CDDP alone) 
According to Fischel et al. [12], if:  
1. R< 0.8, then the association is considered to be synergistic;  
2. 0.8 < R < 1.2, then the association is considered to be additive;  
3. R > 1.2, then the association is considered to be antagonistic.  
  
Immunoblot analysis. Western blotting was performed as previously described [11].  The SIRT3 
antibody (#2627) was from Cell Signaling. To demonstrate equal protein loading, membranes 
were stripped and reprobed with an anti-β-actin antibody (sc-1615, Santa Cruz Biotechnology).  
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Determination of SIRT3 deacetylation activity in HNSCC cells. To determine the effect of 
LC-0296 on SIRT3 deacetylation activity in vivo, HNSCC cells were either control (DMSO) or 
LC-0296 (50 µM) for 18 h. Cells were then lysed and samples were adjusted for protein 
concentration with the BCA protein assay kit (Bio Rad). Samples were then assayed for SIRT3 
deacetylation activity using the fluorogenic SIRT3 Assay Kit (#50083, BPS Bioscience) 
according to manufacturer’s instructions.  
 
Reactive Oxygen Species (ROS) detection assay: To measure the intracellular ROS levels 
under the conditions described in the figure legends, the fluorogenic marker for ROS, carboxy-
H2DCFDA, was used according to manufacturer’s instructions (Invitrogen).  
 
Statistical analysis. Values were expressed as means ± SD. Comparisons between groups were 
determined by one-way analysis of variance (ANOVA) followed by Tukey-HSD multiple-
comparison test. Statistical significance was defined as *p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001. All 
experiments were repeated three times and at least in triplicates when applicable.  
 
Results 
Defining the SIRT3 inhibitor, LC-0296, its chemical structure and its enzymatic selectivity 
in vitro 
The chemical structure and the schematic chemical reaction of LC-0296 are shown in Figure 
4.1A and Figure 4.S1, respectively. The SIRT3 inhibitor, LC-0296, possesses a selective 
inhibitory effect, about ~20 and 10 fold more inhibition on SIRT3 enzymatic activity compared to 
SIRT1 and SIRT2, as shown in Table 4.1.  
 
 
! 72!
SIRT3 inhibitor, LC-0296, inhibits HNSCC cell survival without affecting normal human 
oral keratinocytes 
To assess the effect of the SIRT3 inhibitor, LC-0296, on HNSCC cell survival, we first performed 
dose- and time dependent experiments using a wide range of doses (.001, .01, .1, 1, and 10 µM, in 
24, 48, and 72 h), and compared those to normal human oral keratinocytes (Figure 4.S1). Since 
we did not see significant inhibitory effects on HNSCC cell survival with these doses, we tested 
higher doses of LC-0296. At doses in the µM range, LC-0296 showed significant inhibitory and 
dose-dependent effects on HNSCC cell viability (UM-SCC-1 and UM-SCC-17B) without 
affecting normal human oral keratinocytes (Figure 4.1B). A representative image of HNSCC cells 
(75 µM) treated with LC-0296 is presented in Figure 4.1C. This further demonstrates the absence 
of significant quantitative or morphological changes in the normal human oral keratinocytes 
treated with LC-0296 (Figure 4.1B and C).  
SIRT3 inhibitor, LC-0296, inhibits cell growth and proliferation and promotes apoptosis in 
HNSCC cells 
To further evaluate the effect of the SIRT3 inhibitor, LC-0296, on HNSCC cell growth and 
proliferation, colony formation assays were performed using different doses. Our data 
demonstrate that in addition to inhibiting cell viability, the SIRT3 inhibitor, LC-0296, also 
blocked HNSCC cell colony formation in a dose-dependent manner (Fig. 4.2A). Notably, the 75 
µM dose had an even greater effect on colony formation ability than on cell viability as shown in 
Figure 1B. This may be explained by the fact that single cell colony growth assays are devoid of 
growth signals from neighboring cells and cell-cell contact, thereby promoting a less robust 
survival environment. In addition, LC-0296 not only retarded HNSCC cell growth and 
proliferation, but it also induced apoptosis in a dose-dependent manner (Figure 4.2B and C). 
Importantly, LC-0296, did not exert significant effects on cell growth and proliferation or 
apoptosis on normal human keratinocytes (Figure 4.2D-F).   
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SIRT3 inhibitor, LC-0296, enhances the sensitivity of HNSCC cells to both radiation and 
chemotherapeutic drugs 
Thus far our data indicate that the SIRT3 inhibitor, LC-0296, can be used as a single agent to 
inhibit HNSCC cell growth and survival, and promote apoptosis-mediated cell death. However, 
we further asked whether LC-0296 could function as an effective adjuvant treatment for those 
cases that do not respond well to either radiation or chemotherapeutic approaches. Both UM-
SCC-1 and UM-SCC-17B cells are very aggressive HNSCC cell lines, which are highly resistant 
to radiation [14,15], and the former is also resistant to cisplatin (CDDP) (data not shown). 
Interestingly, LC-0296 worked synergistically to enhance the sensitivity of HNSCC cell lines to 
both treatments compared to untreated controls or cells treated with radiation or CDDP alone 
(Figure 4.3A and B). The synergistic effect was assessed using a combination index (CI). It is 
noteworthy that the synergistic effect was obtained using the 50 µM dose, which is below the IC50  
of LC-0296 in both HNSCC cell lines  (Figure 4.3A and B).  
SIRT3 inhibitor, LC-0296, inhibits SIRT3 deacetylation activity in HSNCC cells 
Previously, we showed that downregulation of SIRT3 levels in OSCC cells significantly limits 
OSCC cell survival and aggressiveness in vitro and in vivo [11]. Although, our novel SIRT3 
chemical inhibitor can selectively inhibit SIRT3 enzymatic activity in vitro (Table 4.1), it was not 
known whether LC-0296, functions by inhibiting SIRT3 deacetylation activity in vivo within a 
cellular context. Therefore, we first assayed for SIRT3 deacetylation activity using cell lysates of 
the two HNSCC cell lines treated with the SIRT3 inhibitor (LC-0296, 50 µM), and compared that 
to untreated controls (DMSO vehicle control, 50 µM). In addition, we performed Western blot 
analyses to assess the effect of LC-0296 on SIRT3 protein levels in vivo.  Our results show that 
LC-0296, inhibits SIRT3 deacetylation activity in vivo without affecting SIRT3 protein levels 
(Figure 4.4A and B).  
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SIRT3 inhibitor, LC-0296, retards cell survival and enhances apoptosis via modulating 
ROS levels in HNSCC cells  
Several studies support that normal cells have lower ROS levels compared to cancer cells [16,17], 
and it is well known that SIRT3 has a key regulatory role in controlling ROS levels in the 
mitochondria [6,18]. Therefore, we hypothesized that the SIRT3 inhibitor, LC-0296, might be 
affecting SIRT3 deacetylation activity, by modulating ROS levels in these cells, and thereby 
affecting their survival and promoting apoptosis. Thus, since ROS levels are higher in cancer 
cells compared to normal cells, this may explain why LC-0296, was more effective on HNSCC 
cells compared to normal human oral keratinocytes. To test this hypothesis, we evaluated ROS 
levels in HNSCC cells compared to normal human oral keratinocytes. In agreement with previous 
studies in other cancer cells [16,17], ROS levels in HNSCC cells were significantly higher than 
those in normal human oral keratinocytes (Figure 4.5A). Next, we measured ROS levels in 
HNSCC cells following LC-0296 treatment. Interestingly, we did find a significant increase in 
ROS levels in the LC-0296 treated HNSCC cells compared to untreated vehicle controls (Figure 
4.5B). In addition, to further confirm that LC-0296 works in HNSCC cells by modulating ROS 
levels, we next used N-Acetyl-Cysteine (NAC), a scavenger for ROS in this context. Indeed, 
addition of NAC abrogated the effect of LC-0296 on HNSCC cells, thus decreasing ROS levels, 
increasing cell viability and decreasing apoptosis (Figure 4.5B-D). Importantly, the modulation of 
ROS levels in HNSCC cells by LC-0296, was associated with retarded cell survival and enhanced 
apoptosis (Figure 4.5C and D). These data show that the SIRT3 inhibitor, LC-0296, possesses a 
specific inhibitory effect on HNSCC cell viability, and enhances apoptosis, at least in part, by 
modulating ROS levels.  
Discussion 
       The poor survival rate for head and neck cancer, urgently summons the development of new 
areas of research that might identify new strategies and approaches for drug development or the 
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discovery of new targets or markers, that could aid in the early diagnosis and treatment of patients 
with head and neck cancer.  
       Sirtuins (SIRT1-7) has been extensively investigated for just over a decade. This field of 
study is an exciting area that seems to hold great promise toward enhancing our understanding of 
and aiding in the development of treatments for age-related diseases such as diabetes, 
neurodegenerative disorders, heart disease, and cancer [4,19]. However, since sirtuin biology is 
still in an early stage of development, there are  controversial viewpoints as to the significance of 
several sirtuins in the area of cancer biology. SIRT1 and SIRT3 seem to be at the focus of this 
controversy [8,9,10,20]. We have devoted our research over the last several years to investigating 
the role of sirtuins in head and neck cancer. Interestingly, we found that of all the known sirtuins 
(SIRT1-7), SIRT3 is specifically overexpressed in oral cancer in vitro and in vivo [11]. This 
overexpression was associated with increased aggressiveness and tumorigenesis in vivo. 
Furthermore, SIRT3 downregulation resulted in reduced tumor burden in vivo, and an enhanced 
sensitivity to both radiation and chemotherapeutic drugs in vitro [11]. In addition, our group 
recently found a role for sirtuins, specifically SIRT3, in promoting anoikis resistance. We found 
that SIRT3 expression levels increased in OSCC cells as they developed an anoikis-resistant 
phenotype compared to their adherent counterparts. This higher SIRT3 expression was associated 
with lower RIP expression levels, and increased tumor burden and incidence in vivo. 
Furthermore, SIRT3 and RIP were oppositely expressed in OSCC tissues. Importantly, stable 
suppression of SIRT3 blocked the anoikis resistant phenotype in vitro and tumor burden in vivo. 
Thus, SIRT3 plays a role in anoikis-resistance that likely contributes to tumorigenesis and 
aggressiveness of OSCC (Y. Kapila’s group, unpublished data under revision). 
       In this study, we report on a novel SIRT3 inhibitor, LC-0296, that has shown an enhanced 
selectivity toward inhibiting SIRT3 deacetylation activity. Importantly, LC-0296, shows 
specificity toward retarding HNSCC cell survival and enhancing apoptosis, without affecting 
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normal human oral keratinocytes. This inhibitor functioned as both a single agent and in 
combination with either radiation or cisplatin (CDDP) treatment to block HNSCC cell viability, 
especially in cell lines that were derived from patients that have shown resistance to these 
treatments.  
       The role of ROS in carcinogenesis/tumorigenesis is well documented in the literature [21,22]. 
ROS is responsible for normal cell transformation, thus promoting tumorigenesis [21,22]. 
However, it is important to keep in mind that normal cells still need low levels of ROS for 
physiologic functions. Thus, the balance between ROS production and antioxidants seems to be a 
key factor in controlling normal cellular processes or abnormal cellular transformation [23,24]. 
SIRT3 seems to be a key regulatory switch in the mitochondria, keeping mitochondrial integrity 
and protecting it from increased ROS levels, thus preventing ROS-mediated cell transformation 
to cancer via deacetylating and activating mitochondrial antioxidants such as MnSOD and SOD2 
[25,26,27]. However, normal cells in general posses lower ROS levels compared to cancer cells 
[16,17], Thus, it seems that after cellular transformation, cancer cells undergo an adaptation to 
increased ROS levels that signifies part of their abnormal genomic dysregulation. Interestingly, 
the balance of ROS levels seems to be a sensor for cellular survival and proliferation, and 
responsible for the increased aggressive phenotype and resistance to conventional cancer 
treatments [22,23,24,28]. Therefore, because SIRT3 is overexpressed in HNSCC cells [11], for a 
reason that is yet unknown, and as part of the abnormal genomic dysregulation in these cells, we 
believe that SIRT3 may be responsible for controlling the balance of ROS levels in  these cancer 
cells. SIRT3 may be keeping ROS levels at a threshold that promotes cancer cell survival, and 
thereby promoting a more aggressive phenotype that resists conventional cancer treatments. 
Given these ideas, we investigated whether LC-0296 works via ROS modulation in HNSCC cells. 
Interestingly, because ROS levels are higher in HNSCC cells compared to normal keratinocytes, 
LC-0296 seems to alter the balance of ROS levels in cancer cells toward retarding cell survival, 
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and enhancing apoptosis. This may also explain, at least in part, the increased sensitivity of IR 
and CDDP resistant HNSCC cells to this drug, especially, when used in combination treatments. 
Although, several studies have shown that the antioxidant, NAC, may function as a 
chemopreventive agent, and it inhibits tumorigenesis in several cancer types including, brain, 
melanoma, and prostate cancers [29,30,31], our data show that in a short pretreatment period, 
NAC alone, did not have a significant effect of HNSCC cell viability and apoptosis. However, 
this pretreatment was sufficient to retard the inhibitory effect of LC-0296 on these cells via the 
reduction of ROS levels. Taking advantage of increased ROS levels in cancer cells is one strategy 
for achieving more potent and selective effects of chemotherapeutic drugs. There are several ROS 
based chemical inhibitors that have been developed and tested in clinical trials with promising 
results [32,33].  
       To our knowledge, there are no published reports on clinical trials using class-III histone 
deacetylase inhibitors (HDAC) of sirtuins to treat cancer. Our current report represents a proof of 
principle wherein treatment with SIRT3 inhibitors may be advantageous for overcoming HNSCC 
aggressiveness and drug resistant phenotypes.  Our novel SIRT3 inhibitor, LC-0296, is the first 
generation of this type of drug, Our group is currently working on developing more potent and 
suitable versions of this drug that may be more applicable for testing within an in vivo setting and 
for potential future clinical trials.  
       In summary, the development of novel SIRT3 inhibitors, such as LC-0296 may open new 
avenues for discovery and development of targeted therapies for HNSCC by taking advantage of 
the increased ROS levels in HNSCC. This may result in better treatment outcomes that are 
associated with fewer side effects, a better quality of life, and improved survival rates for head 
and neck cancer patients.  
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Figure 4.1: SIRT3 inhibitor, LC-0296, inhibits OSCC cell survival without affecting normal 
human oral keratinocytes. (A) The chemical structure of the SIRT3 inhibitor, LC-0296. (B) 
HNSCC cells (UM-SCC-1 and UM-SCC-17B) and normal human oral keratinocytes (k) were 
seeded in 96 well plate at 5 x103 cells/well, then treated with LC-0296, as indicated for 24 h. Cell 
viability was determined by the QUANT Cell Proliferation Assay Kit (Invitrogen). (C) Phase 
contrast images showing the morphology of HNSCC cells (UM-SCC-1 and UM-SCC-17B) and 
normal human oral keratinocytes, after treated with control (DMSO) or LC-0296 (75 µM) for 24 
h.  p-value,  *** p≤ 0.001 LC-0296 vs control (50, 75, 100, and 125 µM).  
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Figure 4.2: SIRT3 inhibitor, LC-0296, inhibits cell growth and proliferation and promotes 
apoptosis in HNSCC cells. (A) Histograms representing the quantification of colony forming 
assay of HNSCC cells (UM-SCC-1 and UM-SCC-17B). Cells were seeded in 6-well plate at 250 
cells/well, treated with LC-0296, as indicated, then cultured for one week. Colonies were fixed 
with methanol, then stained with crystal violet. Number of colonies were presented as the 
percentage of colonies obtained relative to controls. (B) Representative images of HNSCC cells 
(UM-SCC-1 and UM-SCC-17B) stained with DAPI after treated with Control (DMSO) or LC-
0296 as indicated for 24 h. Culture media was collected and centrifuged to collect floating cells, 
which were added back to their respective wells. (C) Fold change of DNA fragmentation in 
HNSCC cells after treated with control (DMSO) or LC-0296 as indicated for 24 h. (D) 
Histograms representing the quantification of colony forming assay, (E) representative images 
DAPI stained cells, (F) fold change of DNA fragmentation, in normal human oral keratinocytes 
(K) after treated with Control (DMSO) or LC-0296 as indicated for 24 h. *** p≤ 0.001.  
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Figure 4.3: SIRT3 inhibitor, LC-0296, enhances the sensitivity of HNSCC cells to both 
radiation and chemotherapeutic drugs. (A) HNSCC cells were treated with LC-0296 (50 µM), 
with or without ionizing radiation (IR, 2.5 Gy) or cisplatin (CDDP, 20 µM) (B) for 24 h, then 
cytotoxicity was determined by the QUANT Cell Proliferation Assay Kit. Control (treatment with 
DMSO vehicle, 50 µM for 24 h). *** p≤ 0.001.  
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Figure 4.4: SIRT3 inhibitor, LC-0296, inhibits SIRT3 deacetylation activity in HSNCC 
cells. (A) HNSCC cells (UM-SCC-1 and UM-SCC-17B) were treated with control (DMSO) or 
LC-0296 (50 µM) for 24 h and lysates were assayed for SIRT3 deacetylation using fluorogenic 
SIRT3 assay kit. Recombinant SIRT3 and NAM, were used as positive controls as per 
manufacturer’s instructions. *** p≤ 0.001. (B) Immunoblots showing SIRT3 expression levels in 
HNSCC cells after treated with LC-0296 as indicated. β-Actin served as loading control.   
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Figure 4.5: SIRT3 inhibitor, LC-0296, retards cell survival and enhances apoptosis via 
modulating ROS levels in HNSCC cells. (A) Normal human oral keratinocytes (K), and 
HNSCC cells (UM-SCC-1 and UM-SCC17B) were seeded in 96 well-plate at 5 x 103 cells/ well, 
then ROS levels were measured after 24 h, using the fluorogenic marker carboxy-H2DCFDA. (B) 
HNSCC cells were pretreated with N-Acetyl-Cysteine (NAC, 20 mM), a scavenger for ROS, or 
control (DMSO) for 2 h, then the pretreatments were removed, and cells were subsequently 
treated with either control (DMSO) or LC-0296 (50 µM) for 10 h, and finally stained with 
carboxy-H2DCFDA for ROS assays. (C) HNSCC cells were treated as in panel B for 12 h, and 
then cell viability was determined by the QUANT Cell Proliferation Assay. (D) HNSCC cells 
were treated as in panel B for 12 h, and then apoptosis was determined using DNA fragmentation 
ELISA. *p≤ 0.05, ** p≤ 0.01 and *** p≤ 0.001.   
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Figure 4.S1: Schematic chemical synthesis of SIRT3 Inhibitor (LC-0296) 
Commercially available 4-nitro-1H-indole (1) was alkylated to give compound 3, whose nitro 
group was reduced to the corresponding amine in compound 4 in excellent yields. The methyl 
ester group in compound 4 was converted into a primary amide with methanolic ammonia. The 
resulting compound 5 was coupled with L-glutamate derived Z-Glu-OMe in the presence of 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole 
(HOBt) to yield LC-0296 in good yields. Reaction conditions (a) NaH, DMF, yield 68%; (b) 
NiCl2·6H2O, NaBH4, MeOH, yield 89%; (c) methanolic NH3, CaCl2, 70 ºC, yield 85%; (d) Z-
Glu-OMe, EDC, HOBt, NMM, CH2Cl2, yield 60%.  
 
Schematic Chemical Reaction 
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Figure 4.S2: The effect of the SIRT3 inhibitor, LC-0296, on HNSCC cells and Keratinocytes 
using wide range of lower drug doses  (A) Normal human oral keratinocytes, (B) UM-SCC-1, 
and (C) UM-SCC-17B, were seeded in 96 well plate at 5 x103 cells/well, then treated with control 
(DMSO) or LC-0296, as indicated for 24, 48, and 72 h. Cell viability was then determined by the 
QUANT Cell Proliferation Assay Kit.  
 
 
Table 4.1: SIRT3 Enzymatic Activity In vitro 
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CHAPTER V 
 
SIRT3 AND CANCER: TUMOR PROMOTER OR SUPPRESSOR? 
 
ABSTRACT 
Sirtuins (SIRT1–7), the mammalian homologues of the Sir2 gene in yeast, have emerging roles in age-
related diseases, such as cardiac hypertrophy, diabetes, obesity, and cancer. However, the role of several 
sirtuin family members, including SIRT1 and SIRT3, in cancer has been controversial. The aim of this 
review is to explore and discuss the seemingly dichotomous role of SIRT3 in cancer biology with 
particular emphasis on its potential role as a tumor promoter and tumor suppressor. This review will also 
discuss the potential role of SIRT3 as a novel therapeutic target to treat cancer. 
 
Introduction  
       Cancer is a leading cause of death worldwide, and the second cause of death in the United States after 
heart disease [1]. Despite advances in technology and improved therapeutic approaches to treat this 
devastating disease, shortcomings remain, especially in treating aggressive and metastatic disease and in 
predicting individual responses to treatment. These observations underscore the complexity of this disease 
and the need for personalized cancer therapy to increase the efficacy of treatment in individual cancer 
patients [2]. Therefore, discovering new pathways that regulate cancer processes is crucial to developing 
better approaches for cancer prevention and treatment.  
The study of sirtuins (SIRT1–7) in cancer tumorigenesis and therapy is an exciting and promising 
new area in cancer research [3,4]. SIRT3 is of particular interest. It regulates both cell death and survival, 
and therefore, a controversy has emerged in the literature about its role as a tumor promoter and/or tumor 
suppressor. In this review, we will explore the controversy to provide the reader with a better 
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understanding of the factors that contribute to this issue, and to discuss future directions and the 
possibility of using SIRT3 as a novel therapeutic target to treat cancer.  
!
Sirtuins: an overview 
       Sirtuins (SIRT1–7) are the mammalian homologues of the silent information regulator 2 (Sir2) first 
discovered in Saccharomyces cerevisiae as an NAD+-dependent histone deacetylase (HDAC). They are 
classified as class III HDACs: they require NAD+ as a cofactor to exert their biological function. They 
contain an evolutionarily conserved core domain, which is essential for their activity as NAD-dependent 
deacetylases or ADP-ribosyltransferases [5,6]. Sirtuin biology is complex, and sirtuins are widely 
expressed in normal tissues [7]. They are involved in a myriad of cellular and tissue functions, such as 
regulating oxidative stress, repairing DNA, increasing genomic stability, and affecting cell survival, 
apoptosis, development, metabolism, aging and longevity [3,4]. Some sirtuins are located in different 
cellular compartments (Fig. 5.1). Those in the same compartment, such as the mitochondrial SIRT3, 4, 
and 5, have different sequences and thus unique and diverse cellular functions and can interact with 
different targets [4,5,6].  
SIRT1 is the best-characterized member of the mammalian sirtuins. It is located predominately in the 
nucleus and modulates cellular stress and survival by deacetylating p53 [8,9], FOXO, and Ku70 [10,11], 
thus promoting tumorigenesis. SIRT1 is thought to have a role in skin, colon, breast and lung cancer, via 
one or more of these mentioned targets [12,13,14,15,16]. It also regulates vascular endothelial 
homeostasis, thereby controlling angiogenesis and vascular function, [17]. Thus, it is likely crucial in 
regulating cell survival, and its functions may contribute to cancer tumorigenesis.  
On the other hand, SIRT1 might be a tumor suppressor [18,19,20]. For example, SIRT1 mutant mice 
possess an impaired DNA repair response, genomic instability, and increased incidence of tumorigenesis. 
Moreover, SIRT1 levels were lower in breast cancer and hepatic cell carcinoma than in normal controls 
!!
89!
[19]. These studies highlight the discrepancy in the literature about the biological functions of SIRT1 and 
underscore the complexity of sirtuin biology (See review by Deng et al. [21]).  
 SIRT2 is found in the cytosol, where it colocalizes with microtubules and deacetylates α-tubulin 
[22]. It controls cell-cycle progression [23] and is downregulated in human gliomas, suggesting a tumor 
suppressor role in brain cancer [24].  
The gene for the nuclear protein SIRT6 is located on chromosome 19p13.3; a region frequently 
affected by chromosomal alterations in acute leukemia [25]. In addition, SIRT6-deficient mice possess an 
aging-like phenotype and genomic instability [26,27].  
SIRT7, which is localized in the nucleolus and functions as a positive regulator of RNA polymerase I-
mediated transcription, is required for cell proliferation and survival [28]. It is located on chromosome 
17q25.3; a region frequently associated with chromosomal alterations in leukemias and lymphomas [29]. 
SIRT7 is also upregulated in breast and thyroid cancers [30,31,32].  
The remaining three sirtuins, SIRT3, SIRT4, and SIRT5, are mitochondrial sirtuins [7,33]. Although 
SIRT4 lacks deacetylation activity, it has weak ADP-ribosyltransferase activity [34,35] and plays an 
important role in insulin regulation [36]. SIRT4 knockout mice are viable, fertile, and display no 
phenotype abnormalities, compared to wild-type littermates, but show increased levels of insulin secretion 
[34]. In contrast to SIRT1 and SIRT3, SIRT4 activity is downregulated by calorie restriction (CR) [34]. 
SIRT5 has less deacetylase activity than SIRT1-3 [37] and remains the least-characterized sirtuin. SIRT5 
is located on chromosome 6p23, an area linked to numerous abnormalities associated with malignant 
diseases, such as acute myeloid leukemia [38]. In contrast to SIRT4- and SIRT5-deficient mice, SIRT3-
deficient mice show greater mitochondrial hyperacetylation than wild-type mice, suggesting that SIRT3 is 
a key mitochondrial deacetylase [39].  
!
 
 
!!
90!
SIRT3 subcellular localization  
       Determining SIRT3’s subcellular localization is important for finding its targets and substrates, 
explaining its cellular functions, and identifying important signaling cascades that may involve it. Human 
SIRT3 is expressed as a full-length 44-kD protein that is targeted to the mitochondria by its N-terminal 
localization sequence [40]. In the mitochondria, SIRT3 is cleaved via the mitochondrial matrix processing 
peptidase (MPP) to a short 28-kD protein, which is important for SIRT3 enzymatic activity [40,41]. 
Others reported that both forms for SIRT3 are enzymatically active [42]. Although most studies support a 
mitochondrial localization for SIRT3 [7,39,40,41,43,44,45,46,47], others suggest that SIRT3 might be 
present in the nucleus [42,47,48]. In addition, Sundaresan et al. reported that, although the long form of 
SIRT3 is found in the nucleus, cytoplasm, and mitochondria, the short form is extensively localized in the 
mitochondria, and during cellular stress, levels of both forms are increased in the nucleus and 
mitochondria of cardiomyocytes [49]. Despite this controversy, one can conclude that SIRT3 exerts a 
major role in the mitochondria and might also have a role in other cellular compartments [50].  
4. SIRT3 and cell survival 
       Mitochondria contain large numbers of key molecules that regulate cell survival, death, and 
metabolic pathways and help to control the balance between health and disease [4,51,52]. For example, 
SIRT3 is critical for maintaining mitochondrial integrity and function. Along with SIRT4, and SIRT5, 
SIRT3 is a mitochondrial sirtuin [33], and SIRT3-/- mice manifest hyperacetylated mitochondrial proteins, 
impaired fatty-acid oxidation, and reduced levels of ATP [39,53,54]. In an early report supporting a 
prosurvival role for SIRT3 in vivo, rodents fasted for 48 h had increased levels of the NAD+ biosynthetic 
enzyme Nampt in their mitochondria. The activity of Nampt, a stress and nutrient-responsive protein 
involved in maintaining cell viability, is regulated by SIRT3 [55]. In addition, under genotoxic stress, 
mitochondrial SIRT3 and SIRT4 were required to protect against genotoxic cell death in human 
embryonic kidney (HEK293) and fibrosarcoma cell lines [55]. 
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       With its central role in mitochondrial biology, SIRT3 contributes to cell survival by modulating 
oxidative stress pathways. Benigni et al. demonstrated that knockout of the angiotensin II type 1 receptor, 
a gene responsible for promoting high blood pressure and various pathological conditions, such as heart, 
kidney and brain diseases, promoted longevity in mice [56]. This receptor knockout was associated with 
increased numbers of mitochondria, attenuation of oxidative stress, and upregulation of Nampt and SIRT3 
levels. SIRT3 protects cardiomyocytes and HeLa cells from genotoxic and oxidative stress-mediated cell 
death. By binding to and deacetylating Ku70, SIRT3 augments Ku70-Bax interactions, prevents Bax 
translocation to the mitochondria, and prevents apoptosis during stress-mediated conditions [49]. In 
addition, SIRT3 protects the heart from cardiac hypertrophy, at least in part, by attenuating reactive 
oxygen species (ROS) [57] and/or by regulating the mitochondrial permeability transition pore (mPTP) 
via deacetylating Cyclophilin-D [58]. SIRT3 utilizes exogenous NAD+ to block cardiac hypertrophy by 
activating the LKB1-AMP kinase pathway [59] (See review by Pillai et. al. [60]).  Under CR conditions, 
SIRT3 deacetylates and activates superoxide dismutase 2 (SOD2), thus protecting cells from ROS-
mediated cell damage [61]. SIRT3 also mediates deacetylation of the evolutionarily conserved lysine 122 
needed for the activity of manganese superoxide dismutase (MnSOD) in response to oxidative stress, thus 
protecting cells from stress-mediated damage [62].  Furthermore, in neurons, SIRT3 acts as prosurvival 
factor, thus protecting neurons from excitotoxic injury such as N-methyl-D-aspartate (NMDA)-induced 
neuronal death [63].  
       SIRT3 also exerts a prosurvival role in multiple cancer pathways. The tumor suppressor, p53 was 
recently identified as a new target for SIRT3 deacetylation in bladder cancer [64]. SIRT3 rescued p53-
induced growth arrest in human bladder tumor–derived EJ-p53 cells, supporting a prosurvival role for 
SIRT3 [64]. Ashraf et al. reported that increased transcriptional levels of SIRT3 were associated with 
lymph node–positive breast cancer, and SIRT3 expression was significantly higher in these samples than 
normal breast biopsies [30]. We recently reported that SIRT3 levels were significantly higher in oral 
squamous cell carcinoma (OSCC) cell lines and human OSCC tissue microarray samples (TMAs) than in 
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normal controls [65]. Furthermore, SIRT3 downregulation inhibited cell growth and proliferation and 
increased the sensitivity of OSCC cells to radiation and chemotherapy treatments. To further demonstrate 
the role of SIRT3 in oral cancer carcinogenesis in vivo, we used a floor-of-mouth oral cancer murine 
model that mimics human OSCC [66,67] to study the effect of SIRT3 downregulation on OSCC tumor 
growth in immunodeficient mice. Downregulating SIRT3 reduced tumor burden in vivo, implicating a 
prosurvival role for SIRT3 in oral cancer [65].  
Anoikis, apoptotic cell death triggered by loss of extracellular matrix (ECM) contacts, is dysregulated 
in many chronic debilitating and fatal diseases, including cancer, and resistance to anoikis contributes to 
the development and progression of cancer [68,69,70]. We recently reported that anoikis activates a 
CD95/Fas-mediated signaling pathway regulated by receptor interacting protein (RIP), a kinase that 
shuttles between CD95/Fas-mediated cell death and integrin/FAK-mediated survival pathways in oral 
squamous cell carcinoma (OSCC) cells [69]. Interestingly, we found that, as OSCC cells become resistant 
to anoikis, their SIRT3 expression increases and their RIP expression decreases. These cells exhibit a 
greater tumor burden in vivo. Additionally, SIRT3 is highly expressed in OSCC tissues and cells, where 
its expression pattern is opposite to that of RIP expression (Kapila lab; unpublished data). Thus, these 
observations suggest that SIRT3 may play a role in mediating anoikis resistance and tumorigenesis.  
In summary, SIRT3 promotes survival and protects several cell types from cellular damage by 
maintaining mitochondrial integrity and functions and by enhancing their resistance to stress-mediated 
cell death. Similarly, SIRT3 overexpression in cancer cells promotes survival signals while suppressing 
apoptotic signals, thereby enhancing tumorigenesis (Fig. 5.2).  
 
SIRT3, apoptosis, and cell death 
       In contrast, other reports support a proapoptotic role for SIRT3. SIRT3 induces growth arrest and 
apoptosis in several colorectal carcinoma and osteosarcoma cells and in non-cancer human cell lines, such 
as retinal epithelial and lung fibroblast cells [71]. This action is mediated, in part, by SIRT3 modulation 
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of the JNK2 signaling pathway in these cell lines [71]. Interestingly, the same group reported earlier that 
SIRT1 and JNK2 function as constitutive suppressors of apoptosis in colorectal carcinoma [72]. Thus, 
SIRT1 and SIRT3 have opposite roles in colorectal carcinoma. A similar observation was made in 
neurons [73], however, the role of SIRT3 in neurons is still controversial [63]. In leukemia cell lines, 
treatment with Kaempferol, a flavonoid that auto-oxidizes and generates ROS, induces apoptosis via 
increasing Bax and SIRT3 levels and activating caspase-3 cascades [74].  
Recently, SIRT3 was reported to suppress tumors. Kim et al. implanted SIRT3-/- mouse embryonic 
fibroblasts (MEFs) expressing Myc/Ras into the hind limbs of nude mice. After 3 weeks, these mice 
developed tumors, but mice implanted with SIRT3+/+ Myc/Ras, SIRT3-/- Myc, or SIRT3-/- Ras MEFs did 
not. Importantly, SIRT3 knockout MEFs did not undergo spontaneous immortalization or possess a 
tumorigenic phenotype, unless they became immortalized by the action of Myc or Ras. This 
transformation-permissive phenotype was mediated by increased levels of ROS, chromosomal instability, 
and altered intracellular metabolism. Some SIRT3-/- mice developed mammary tumors over the 24-month 
observation period. In addition, SIRT3 expression was found to be decreased in commercially obtained 
TMAs of human breast cancer samples and in other cancers (glioblastoma, prostate, head and neck, and 
others), based on a review of gene expression data from other sources [75]. These findings suggest that 
SIRT3 is a tumor suppressor. In agreement with this report, others found that, in breast cancer patients, 
SIRT3 levels were lower or undetectable in most of the samples than in normal individuals, and 
specifically breast and ovarian cancers were frequently associated with focal deletion of the SIRT3 gene. 
Additionally, tumors lacking SIRT3 (SIRT3-KO-MEFs transformed with Ras and E1a oncogenes) grew 
faster and were bigger than transformed SIRT3-WT tumors in a xenograft model. This downregulation 
was associated with upregulation of hypoxia inducible factor-1 α (HIF1-α) targeted genes [76]. Similarly, 
Bell et al. also demonstrated a tumor suppressor role for SIRT3 in human colon carcinoma and 
osteosarcoma cells, via the ability of SIRT3 to negatively regulate ROS and HIF1-α [77]. 
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In HEK-293 cells, the transient receptor potential melastatin-related channel 2 (TRPM2), a 
nonselective cation channel, confers susceptibility to cell death in response to oxidative stress. This cell 
death was reduced by treating with the general sirtuin chemical inhibitor, NAM, and with selective 
downregulation of both SIRT3 and SIRT2 [78], thus supporting a proapoptotic role for these sirtuins in 
the context of TRPM2 and oxidative stress. SIRT3 also deacetylates cyclophilin D, a protein required for 
hexokinase II binding to voltage-dependent anion channels (VDACs) to maintain mitochondrial integrity. 
Thus, in some cancer cells, SIRT3 induces hexokinase II to dissociate from the mitochondria and activate 
apoptosis. However, in non-transformed cells, activation of SIRT3 may prevent necrotic cell death [79]. 
From these findings, SIRT3 seems to function as a proapoptotic signal in some cancer and non-cancer cell 
lines, and it may prevent a transformation-permissive phenotype in certain normal cells, thus guarding the 
cell as a tumor suppressor (Fig. 5.2).  
 
SIRT3, metabolism, and cancer  
       Metabolism is important in cancer development and prevention [80]. Cancer cells are metabolically 
active and need ATP to maintain their growth, proliferation, and survival [81,82]. Thus, understanding 
how specific regulators of metabolism are altered in cancer will be very helpful for developing therapies. 
Furthermore, cancer cells shift their mode of ATP/energy production from oxidative phosphorylation to 
glycolysis. This is called the “Warburg effect” [83,84]. However, cancer cells can switch between 
glycolysis and fatty acid oxidation, depending on the environment and substrate availability. This 
suggests that targeting one metabolic pathway may not be sufficient as a treatment strategy, since this 
may lead to resistance and more aggressive cancer phenotypes [85,86]  
Mitochondria are important determinants of energy regulation, metabolic homeostasis, and cellular 
lifespan [52,87,88], and in the mitochondria, SIRT3 regulates numerous metabolic processes, such as 
fatty-acid oxidation, oxidative phosphorylation, and the TCA cycle. These observations implicate SIRT3 
as a key regulator of cancer processes. Several studies have highlighted the role of SIRT3 in metabolism 
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and homeostasis and revealed new targets and substrates for SIRT3-dependent deacetylation [33,89]. 
However, few linked SIRT3-regulated metabolism to cancer. Those that addressed SIRT3 as a tumor 
suppressor demonstrated that SIRT3-/- mice have depleted levels of ATP: about 50% less in the heart, liver 
and kidney, and increased ROS production than in wildtype mice [54,75]. Indeed, increased ROS levels 
promote mutagenesis and genomic instability [90], as was the presumed case in SIRT3-/- mice [75]. In 
addition, SIRT3 critically regulates the Warburg effect. Thus, SIRT3 mediates metabolic destabilization 
of HIF1-α, a factor that regulates the metabolic shift to glycolysis in cancer cells, and its upregulation is 
associated with tumorigenesis [76,77].  
SIRT3 regulates mitochondrial energy homeostasis. More specifically, it maintains ATP basal levels 
by regulating mitochondrial electron transport by deacetylating the 39-kD protein NDUFA9 [54] and 
succinate dehydrogenase [91]. Moreover, ATP synthase (ATP5A) and the chaperone protein HSP70, 
which protect against oxidative stress, are targets for SIRT3 [92]. SIRT3 also regulates fatty-acid 
oxidation by deacetylating long-chain acyl coenzyme A dehydrogenase (LCAD), thereby augmenting its 
enzymatic activity. Mice lacking SIRT3 have hyperacetylated LCAD and fatty-acid oxidation disorders 
during fasting, including reduced ATP levels, hypoglycemia, and cold intolerance [53]. SIRT3 
downregulation in the hepatocyte cell line, HepG2, results in dysfunction in the electron transfer chain, 
reduction of mitochondrial membrane potential, and increased levels of ROS [47]. The first discovered 
target of SIRT3-mediated deacetylation was acetyl-CoA synthetase 2 (AceCS2). SIRT3 deacetylates and 
activates AceCS2, an enzyme important in converting acetate to acetyl-CoA in the presence of ATP and 
CoA, an enzyme required for TCA (Krebs) cycle initiation [93,94,95]. Since SIRT3 also modulates 
several enzymes of the TCA cycle, including isocitrate dehydrogenase 2 (IDH2), this is yet another 
mechanism by which SIRT3 helps to modulate energy production from carbohydrates, fats, and proteins 
[96]. In addition, under CR conditions, SIRT3 seems to modulate IDH2 function and protect the cell from 
oxidative stress-induced cell death [97]. Interestingly, mutations of IDH2 are associated with some cancer 
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types, such as gliomas and acute myeloid leukemias; however, the use of IDH2 as a potential therapeutic 
target is still controversial [98,99,100].  
Shi et al. demonstrated that SIRT3 regulates thermogenesis by modulating mitochondrial proteins, 
such as peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1α) and the 
uncoupling protein 1 (UCP1) [44]. On the other hand, SIRT3 is a target for PGC-1α, whereby ROS levels 
are regulated in the cell [101]. PGC-1α itself has important metabolic roles, including regulating adaptive 
thermogenesis, gluconeogenesis, mitochondrial biogenesis, and respiration, and it protects cells against 
ROS generation and damage. PGC-1α binds to the SIRT3 promoter, enhancing its expression and 
downstream signaling pathways, including the activation of anti-oxidants SOD2 and catalase [101].  
Moreover, SIRT3 levels are lower in obese mice than in normal littermates, thus implicating a role for 
SIRT3 in controlling obesity [44]. Additionally, ob/ob mice treated with leptin, a key hormone in 
regulating fat metabolism and energy expenditure, showed increased levels of SIRT3, further supporting a 
role for SIRT3 in controlling obesity [102]. SIRT3 regulates ketone body production during fasting via 
deacetylating the mitochondrial protein 3-hydroxy-3-methylglu-taryl CoA synthase 2 (HMGCS2) [103], 
providing further evidence of the important roles of SIRT3 in regulating cellular metabolism.  
In aggregate, although few studies have linked SIRT3-mediated metabolism directly to cancer, all 
these studies support a role for SIRT3 as a critical regulator of metabolism in the mitochondria, which in 
turn, participates in cancer development or prevention. Additionally, age-related diseases share common 
risk factors and perhaps even redundancy in their mechanisms of pathology [104]. Therefore, determining 
the role of SIRT3 in those diseases may help better define its potential role in their etiology and in the 
development of novel therapeutics.  
 
Is SIRT3 a tumor promoter or suppressor?  
       Cancer cells possess six common traits including self-sufficiency in growth signals, insensitivity to 
antigrowth signals, evading apoptosis, sustained angiogenesis, limitless replicative potential, and tissue 
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invasion and metastasis [105]. In addition, emerging hallmarks and enabling characteristics in cancer cells 
include dysregulation of cellular energy and avoidance of immune distraction, and the consequences of 
genomic instability and tumor-promoting inflammation are factors that contribute to creating a 
tumorigenic microenvironment, thus further facilitating and supporting the unique features of cancer cells 
phenotype [82]. The fact that SIRT3 can regulate most of these cancer processes, implicates SIRT3 as a 
novel potential therapeutic target to treat cancer. However, the discrepancy in the literature regarding the 
role of SIRT3 in cancer complicates how best to develop SIRT3 as a potential target for cancer therapy. It 
may be most appropriate to consider the cell-dependent context, the background of each cell line tested, 
and the influence of different dysregulated pathways in these cell lines, as in the case for SIRT1 in colon 
cancer [14].  
The finding that SIRT3 is overexpressed in metabolically active tissues, such as the heart, where 
SIRT3 protects against genomic and stress-mediated apoptosis, at least in part, via ROS reduction and 
increases in Ku70-Bax interactions [49,57], is one mechanism by which cancer cells that overexpress 
SIRT3 similarly resist cell death. This was indeed demonstrated by the same group in the HeLa cervical 
cancer cell line [49].  
SIRT3 is overexpressed to a greater extent in several human oral cancer cells and tissues than in 
normal controls, and SIRT3 downregulation in these cells inhibited OSCC cell growth and proliferation 
and enhanced radio- and chemo-therapeutic drug cytotoxicity. These observations suggest that these cells 
rely on SIRT3 signaling for survival. In addition, SIRT3 downregulation in OSCC cells in vivo reduced 
tumor burden in mice [65], further underscoring the critical role of SIRT3 in promoting survival and 
tumorigenesis in OSCC. Moreover, under suspension conditions, oral cancer cells aggregate to become 
anoikis resistant, maintaining their survival signals to escape suspension-induced cell death. One of those 
survival signals seems to be mediated by increased SIRT3 expression levels (Kapila lab, unpublished 
data).  
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Nampt protection against cell death, which was dependent on SIRT3 expression in fibrosarcoma cells 
[55], and the ability of SIRT3 overexpression to rescue p53-induced cell growth arrest in human bladder 
cancer [64], also demonstrate a prosurvival role for SIRT3 in these tumors. Overexpression of SIRT3 in 
lymph node-positive breast cancer, implicates a role for SIRT3 in advanced stages of breast cancer [30]. 
Together, these findings support a prosurvival role for SIRT3 in cancer, and the concept that SIRT3 
functions as a tumor promoter in these tumors.  
In contrast to the findings of Ashraf et al. [30], others showed that SIRT3 levels were lower in human 
breast cancer samples than in normal controls, and SIRT3 levels were further downregulated in advanced 
stages of breast cancer, supporting an opposite role for SIRT3 in breast cancer [75,76]. Interestingly, Kim 
et al. showed that MEFs from SIRT3 knockout mice did not become immortalized spontaneously. 
Instead, they required at least one oncogenic hit with either Myc or Ras to become immortalized in vitro 
and both Myc and Ras to develop tumors in vivo [75]. This suggests that environmental or genetic factors 
control how SIRT3 functions in cells. In addition, this group found that seven out of twenty SIRT3 
knockout mice developed mammary tumors over a 24-month period, while none of the SIRT3 wildtype 
mice developed tumors [75]. However, after abrogating the function of an important cellular regulator 
such as SIRT3, 24 months is a reasonable time for genomic alterations and mutations to accumulate, 
which are critical initiating factors in the multistep process of cancer development [106,107]. 
Additionally, since SIRT3 is a critical regulator of the Warburg effect in cancer cells, downregulation of 
SIRT3, such as in breast cancer, would be associated with increased levels of ROS and a shift in 
metabolism toward glycolysis via the upregulation of HIF1-α and its targeted genes [76]. Moreover, in 
human colon carcinoma and osteosarcoma cells, SIRT3 also suppresses, ROS, HIF1-α and its targeted 
genes. Thus, colon carcinoma cells with stable knockdown of SIRT3 demonstrated enhanced 
tumorigenesis in a xenograft model, and augmented HIF1-α protein stability and transcriptional activity 
compared to controls [77].  
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In contrast, tumors with high levels of SIRT3 as part of their genomic and signaling dysregulation 
could take advantage of this overexpression to sustain their survival signals by downregulating ROS 
levels and maintaining high amounts of ATP/energy sufficient for their cancer cell machinery. In this 
regard, reduced levels of ROS were associated with higher levels of antiapoptotic mitochondrial proteins, 
such as Bcl-2 and Bcl-xL in OSCC cells [108]. Interestingly, ROS differentially regulates apoptosis and 
malignant transformation in several cancer types by regulating Bcl-2 [109,110]. Thus, superoxide plays a 
proapoptotic role by downregulating and degrading Bcl-2 proteins by ubiquitination, whereas nitric oxide 
(NO)-mediated S-nitrosylation of Bcl-2, abrogates its ubiquitination and subsequent proteosomal 
degradation [109,110]. In addition, Bcl-2 family proteins have been linked to resistance to cancer therapy 
in B-cell lymphomas and oral cancer [111,112,113]. It would be interesting to study the role of SIRT3 in 
modulating Bcl-2 family proteins in these cancer cell types. 
Interestingly, SIRT1 is overexpressed in drug-resistant cancer cells, including neuroblastoma, 
osteosarcoma, mammary, and ovarian carcinomas [114]. Similarly we found that two OSCC cell lines 
(UM-SCC-1 and UM-SCC-17B) that are highly resistant to radiation and cisplatin treatment [115,116] 
become sensitive to low doses of both treatments only when SIRT3 levels were downregulated. This 
suggests a role for SIRT3 in resistance-mediated mechanisms in oral cancer. This resistance could be 
mediated by regulating Bcl-2 family proteins or related signaling cascades via SIRT3-ROS modulation. 
These mechanisms are currently under investigation in our laboratory.  
Additionally, depending on SIRT3 levels, current evidence suggests that SIRT3 controls 
mitochondrial ROS directly or indirectly in the cell [60,89], thereby dictating the fate of a given cell type. 
Therefore, a cell either undergoes damage and assumes an environmentally-permissive neoplastic 
phenotype [62,75,76,117] or a protective/stress-mediated resistance and undergoes cell survival 
[49,57,61,62,97].   
 Interestingly, contrasting findings highlight the dichotomy of SIRT3’s role in cancer processes in 
different cancer cell types. We found in oral cancer and others found in fibrosarcoma, cervical cancer, and 
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bladder cancer that SIRT3 was required to protect these tumors from stress-mediated cell death by various 
stimuli [55,57,64,65]. Others showed that SIRT3 was required to suppress tumorigenesis, and to induce 
stress-mediated cell death in tumors, including colorectal carcinoma, osteosarcoma, leukemia, and breast 
cancer [71,74,75,76,77]. Furthermore, the recent findings that SIRT3 might deacetylate cyclophilin-D, 
resulting in either enhancing apoptosis in transformed cells such as HeLa cells [79] or promoting survival 
and protecting against age-related cardiac hypertrophy [58], clearly show that SIRT3 may function 
differently depending on cell type. Even in normal cells such as neurons, SIRT3’s role also seems to be 
controversial [63,73].   
Thus, SIRT3’s function varies in different normal and tumor tissues and may be cell- and tumor-type 
specific. Its role must not be generalized, but should be examined in each cancer type separately to 
determine whether it functions as a tumor promoter or suppressor. More importantly, the genetic or 
epigenetic alterations that underlie cancer initiation and progression may differ from individual to 
individual even within the same cancer type, resulting in a dysregulation of different signaling cascades 
that may or may not depend on SIRT3. These issues complicate our ability to predict the importance of 
SIRT3 in a given carcinogenic event. Therefore, looking at the bigger picture by screening cancer patients 
to analyze their genomic, epigenomic, proteomic, and metabolomic profile will help discover the 
dysregulated pathways that lead to a given disease, and thereby help maximize and personalize the 
therapeutic approaches for each patient.  
 
 
Sirtuins as potential therapeutic targets for cancer  
       Several studies have implicated sirtuins as novel therapeutic targets for many age-related diseases, 
including cancer, but how sirtuins are involved in cancer is still not clear and controversial. In this review, 
we want to highlight the discrepancies in the literature about the roles of sirtuins in cancer, especially 
those of SIRT1 and SIRT3. A clear understanding of how individual sirtuins are involved in different 
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cancer types is important for assessing their potential in possible therapies. Sirtuins seem to be involved 
in tumorigenesis, and thus, sirtuin inhibitors/modifiers might have therapeutic benefit. Several inhibitors 
and activators of sirtuins have been tested in different cancer cell lines, but few have been tested in vivo 
[51]. The sirtuin inhibitors, sirtinol and splitomicin, induced senescence-like growth arrest in breast and 
lung cancers [118]. NAM, another sirtuin inhibitor, induced apoptosis in lung cancer [8]. We 
demonstrated that sirtinol and NAM inhibited cell growth and proliferation and induced apoptosis in oral 
cancer cells [65]. Treatment of B-cell lymphoma cells with cambinol, a SIRT1 inhibitor, inhibited tumor 
cell growth and induced apoptosis in vitro, and reduced tumor size compared to controls in vivo [119]. 
Moreover, cambinol sensitized lung cancer cells to the DNA-damaging agent etoposide, thus inducing 
cell death and etoposide-induced cell-cycle arrest [119] (See review by Balcerczyk et al. [120]). 
Resveratrol, a polyphenol phytoalexin and natural component found in the skin of red grapes and red 
wine, works as an activator of sirtuins and possesses diverse natural therapeutic benefits, including 
cardiac protection, anti-inflammatory and anti-carcinogenic effects, preventing obesity, and promoting 
longevity [121,122]. These therapeutic benefits seem to work, at least in part, by activating SIRT1 and 
SIRT3, although it is not yet clear whether these effects are mediated by direct or indirect mechanisms 
[121,122,123,124]. Interestingly, resveratrol modulates both survival and death signals, depending on the 
administered dose in vivo [125]. At low doses (2.5 or 5 mg/kg for 14 days in rats), resveratrol provided 
cardiac protection and lower levels of apoptosis than controls. In contrast, at high doses (25 or 50 mg/kg), 
resveratrol hindered cardiac function and promoted apoptosis of cadiomyocytes. The former effect was 
mediated by augmenting survival signaling pathways, including p-Akt, NFκB, and Bcl-2 activation. The 
latter was mediated by switching on the death program by repressing the same pathways [125]. Moreover, 
resveratrol is the most studied sirtuin activator in cancer prevention. Many studies have shown resveratrol 
to be a natural anticarcinogenic agent, modulating different stages of cancer, including initiation, 
promotion, and progression in neuroblastoma, hepatoma, breast, lung, pancreatic, and prostate cancers in 
vitro or in vivo [126,127]. However, many of these studies yielded contradictory results even in the same 
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tumor type. We reasoned that these discrepancies could be due to the different experimental approaches 
used to examine resveratrol. For instance, some data were collected from mice and others from rats. Some 
studies used animal carcinogenesis models with different genetic backgrounds, others used different doses 
of resveratrol, and yet others used different time frames for drug administration. Resolving these 
discrepancies would be very helpful. In addition, these drugs are all generalized inhibitors or activators of 
several sirtuin family members. Thus, some redundancy or even opposing actions of some sirtuin 
functions may be expected. Furthermore, different tumors have different genetic backgrounds that differ 
from one person to another. This diversity may explain why one patient responds well to a specific 
treatment but another patient with the same type of cancer does not.  
The rapidly evolving era of personalized medicine holds great promise for the future of cancer 
therapy. For example, the use of RNA interference (RNAi) as a specifically targeted therapeutic approach 
may be useful especially in combination with conventional treatments. Currently, studies using RNAi are 
still in early stages of clinical trials. RNAi has been tested in different types of cancer, such as lung, 
advanced liver, and chronic myeloid leukemia. We recently used an OSCC floor-of-mouth model in 
which mice treated with shRNA-modified-OSCC cells to reduce SIRT3 levels had a lower tumor burden 
than controls [65]. This demonstrates the usefulness of targeted gene knockdown as a potential 
therapeutic approach (See review by Phalon et al. [128]).      
Class-I and II HDAC inhibitors have been tested in phase-I and II clinical trials with or without 
conventional chemotherapeutic drugs. The agents were well tolerated with low toxicity and yielded 
promising results. Some of the agents used include phenyl acetate, suberoylanilide hydroxamic acid, and 
Trichostatin to treat patients with solid tumors, hematologic malignancies, and advanced leukemias [129]. 
To our knowledge, there are no published reports on clinical trials using class-III HDAC inhibitors of 
sirtuins to treat cancer. However, class-III HDAC activators of sirtuins such as resveratrol are currently in 
early stages of clinical trials, and have been tested for safety and potential treatment of age-related 
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diseases such diabetes, neurodegenerative disorders and cancer (See references [130,131] about ongoing 
and published clinical trials).  
!
Conclusions 
       We are just beginning to appreciate the role of sirtuins in treating age-related diseases, such as 
cancer. However, the current controversy regarding the role of SIRT3 in cancer, emphasizes the 
importance of examining this area further. Data support that SIRT3 can function as a tumor promoter or 
suppressor, depending on the cell- and tumor-type and the presence of different stress or cell death 
stimuli. Also, genetic and environmental factors underlying cancer initiation and development in each 
patient may contribute to this discrepancy. Thus, it is important to carefully examine the role of SIRT3 in 
each tumor type separately and in both in vitro and in vivo settings. Understanding the mechanistic 
differences in tumor types will enhance our knowledge of the complex biology of sirtuins in cancer and, 
ultimately, help us develop better therapeutic approaches. Therefore, screening cancer patients for 
genomic, proteomic, and metabolomic abnormalities and dysregulated signaling cascades to highlight 
important alterations might help identify useful targets for personalized cancer therapy and more 
successful cancer treatment.  
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Figure 5.1: Sirtuins subcellular localization: SIRT1 is predominantly located in the nucleus, and also in the 
cytosol. SIRT2 is localized in the cytosol. SIRT3, SIRT4, and SIRT5 are mitochondrial proteins, but SIRT3 may 
also be found in the nucleus and cytosol under different cellular events.  SIRT6 and SIRT7 are localized in the 
nucleus and nucleolus, respectively. 
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Figure 5.2: SIRT3 diverse cellular functions. (Rt) The role of SIRT3 in survival, cell protection, and tumor 
promotion. Nicotinamide phosphoribosyltransferase (Nampt), a stress and nutrient-responsive gene, protects against 
genotoxic cell death via SIRT3 upregulation.  Gene knockout (KO) of Ang II promotes longevity in mice either 
directly or indirectly through Nampt or SIRT3 upregulation. SIRT3 deacetylates Ku70, augmenting Ku70-Bax 
interaction, thus attenuating apoptosis and promoting cell survival in cardiomyocytes. In the heart, SIRT3 also 
prevents cardiac hypertrophy by attenuating reactive oxygen species (ROS), deacetylating cyclophilin-D, and 
activating the anti-hypertrophic LKB1-AMP kinase signaling pathway. Calorie restriction (CR) prevents aging and 
age-related diseases by augmenting SIRT3 levels and functions in the cell, at least in part, by deacetylating and 
activating superoxide dismutase 2 (SOD2), thus protecting the cell from ROS-induced cell death. In addition, 
ionizing radiation (IR) in normal cells may enhance SIRT3-deacetylated-MnSOD activation, therefore, again 
protecting the cell from ROS-induced cell death. Although it is still controversial, in neurons SIRT3 seems to protect 
cells from excitotoxic injury such as N-methyl-D-aspartate (NMDA)-induced neuronal death. SIRT3 deacetylates 
p53, attenuating p53-BAG2 complex stability (BAG2; BCL2-associated athanogene 2), thus decreasing apoptosis. 
Lymph node–positive breast cancer is associated with increased levels of SIRT3. SIRT3 is also overexpressed in 
oral cancer and in anoikis-resistant oral squamous cell carcinoma (OSCC) cells, thus promoting OSCC cell survival 
and preventing anoikis-mediated cell death.. (Lt) The role of SIRT3 in apoptosis, cell death, and tumor 
suppression. In colorectal carcinoma, Bcl-2 knockdown (KD) was associated with SIRT3 upregulation and 
apoptosis by deacetylating AceCS2 and switching on the JNK2 signaling pathway. In neurons, low potassium (LK)-
induced apoptosis is mediated by SIRT3.  In leukemia, the treatment with Kaempferol, a flavonoid that auto-
oxidizes and generates ROS, induces apoptosis by SIRT3 and Bax upregulation, thus switching on caspase-3 
cascades and apoptosis. SIRT3 is downregulated in human breast cancer cells compared to normal controls, and 
SIRT3-/- mice developed mammary tumors over a 24-month period. In human colon carcinoma and osteosarcoma 
cells, SIRT3 also works as a tumor suppressor by suppressing ROS and HIF1-α. In HEK-293 cells, the transient 
receptor potential melastatin-related channel 2 (TRPM2), a nonselective cation channel induces cell death in 
response to oxidative stress via SIRT3.Unlike non-transformed cells, in some cancer cells, SIRT3 deacetylates 
cyclophilin-D, inducing the dissociation of hexokinase II/VDAC complex in the mitochondria, thus activating 
apoptosis.  
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CHAPTER VI 
 
CONCLUSIONS  
 
SUMMARY 
 
       The poor survival rate of head and neck cancer, which stands at approximately 50%, 
underscores the urgent need to explore new areas of research and develop new therapeutic drugs 
and approaches that can help improve the survival rate of head and neck cancer patients. 
       Sirtuins (SIRT1-7) have been extensively investigated for just over a decade. This field of 
study is an exciting area that seems to hold great promise toward enhancing our understanding of 
and aiding in the development of treatments for age-related diseases, such as diabetes, 
neurodegenerative disorders, heart disease, and cancer [1,2]. However, since sirtuin biology is 
still in an early stage of development, there are  controversial viewpoints as to the significance of 
several sirtuins in the area of cancer biology. SIRT1 and SIRT3 seem to be at the focus of this 
controversy [3,4,5,6]. Thus, expanding the study of sirtuins in this area of research will advance 
the field and help us to better understand the mechanisms by which sirtuins can regulate different 
cancer processes. Sirtuins control cancer cell proliferation and survival, cell cycle progression, 
apoptosis, angiogenesis, and metabolism [2,7,8,9]. This implicates sirtuins as novel potential 
therapeutic targets to treat cancer [10].  Furthermore, the role of sirtuins in head and neck cancer 
has not yet been investigated.  Thus, the aim of this dissertation work was to investigate whether 
sirtuins play a role in head and neck cancer tumorigenesis, and whether sirtuins can be used as 
novel sole or adjunctive therapeutic targets for HNSCC, thereby improving the survival rates for 
head and neck patients. 
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       Here, we show for the first time a novel role for sirtuins, and specifically, sirtuin-3 (SIRT3), 
in head and neck cancer tumorigenesis. Our data support that of all the sirtuin family members, 
SIRT3 is specifically overexpressed in OSCC in vitro and in vivo compared to normal controls. 
SIRT3 downregulation enhanced the sensitivity of OSCC cells to both radiation and 
chemotherapeutic drugs. In addition, SIRT3 downregulation inhibited OSCC cell growth and 
proliferation in vitro, and reduced tumor burden in vivo.  
       We also show a link between SIRT3 and anoikis, apoptotic cell death triggered by loss of 
extracellular matrix (ECM) contacts. Interestingly, we found that SIRT3 and receptor interacting 
protein (RIP) are oppositely expressed in OSCC, and that OSCC cells escape anoikis by forming 
multicellular aggregates or oraspheres to maintain their survival compared to single cells, which 
undergo anoikis-mediated cell death. Additionally, anoikis-resistant OSCC cells that possess 
higher SIRT3 and lower RIP expression induced an increased tumor burden and incidence in 
mice unlike their adherent OSCC cell counterparts. Furthermore, stable suppression of SIRT3 
inhibits anoikis-resistance and reduces tumor incidence. These findings suggest that SIRT3 may 
be a new potential therapeutic target to treat head and neck cancer patients.   
       To our knowledge, there are no published reports on clinical trials using class-III histone 
deacetylase inhibitors (HDAC) of sirtuins to treat cancer. Therefore, we next thought to 
investigate the use of a novel SIRT3 inhibitor, LC-0296, on HNSCC cells that are radio-resistant 
and originated from patients that resisted conventional therapy [11,12,13]. Interestingly, our data 
suggest that LC-0296 has a selective inhibitory effect on SIRT3 deacetylation activity compared 
to SIRT1 and SIRT2, the best characterized sirtuin family members with deacetylation activity 
[14]. Importantly, LC-0296, shows specificity toward retarding HNSCC cell proliferation and 
survival, and enhancing apoptosis, without affecting normal human oral keratinocytes. 
Additionally, LC-0296 not only worked as a single agent in HNSCC, but it can also be combined 
with and exert a synergistic effect with both radiation and cisplatin treatments, especially in cell 
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lines that were derived from patients that have shown resistance to conventional treatment. 
Because the literature supports that ROS levels are increased in cancer cells compared to normal 
cells [15,16], and SIRT3 plays a key role in regulating ROS levels in cells [9,17], we investigated 
whether LC-0296 would exert its inhibitory effect on SIRT3 deacetylation activity via modulating 
ROS levels in HNSCC cells. This, could them explain, in part, the selectivity of LC-0296’s 
inhibitory effect on HNSCC cells compared to normal keratinocytes. In agreement with 
previously published reports in other cancer types [15,16], ROS levels were higher in HNSCC 
cells compared to normal oral keratinocytes. In addition, LC-0296 treatment further increases the 
levels of ROS in HNSCC cells compared to untreated controls. To further confirm that LC-0296 
mediates its effect by modulating ROS levels in HNSCC cells, we next used N-Acetyl-Cysteine 
(NAC), a scavenger for ROS to challenge this mechanism. Indeed, NAC was able to inhibit the 
effects of LC-0296, in HNSCC cells, thus decreasing ROS levels. Importantly, the modulation of 
ROS levels in HNSCC cells by LC-0296, was associated with retarded cell survival and enhanced 
apoptosis. These data demonstrate that the SIRT3 inhibitor, LC-0296, mediates its inhibitory 
effect on HNSCC cells, at least in part, by modulating ROS levels. Our novel SIRT3 inhibitor, 
LC-0296, is the first generation of this type of drug. Our group is currently working on 
developing more potent and suitable versions of this drug that may be more applicable for testing 
within an in vivo setting and for potential future clinical trials.  
       Interestingly, inhibition of SIRT3 enzymatic activity had no additional effects on ROS levels 
in the context of stable SIRT3 suppression in HNSCC cells (Figure 6.1). This suggests that LC-
0296 works mainly via inhibiting SIRT3 in HNSCC cells.   
       In agreement with other reports on the role of SIRT3 in fibrosarcoma, cervical cancer, and 
bladder cancer [18,19,20], our data demonstrate that SIRT3 plays a protective and prosurvival 
role in HNSCC via modulating cell survival and proliferation, and protecting HNSCC cells form 
apoptosis, at least in part, by modulating ROS levels.  
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Finally, in an effort further explore the role of SIRT3 in tumorigenesis, and to examine 
whether SIRT3 is a tumor promoter or suppressor, we reviewed these topics and presented them a 
review paper. This review highlights that SIRT3 might have a dual role in cancer, as a tumor 
promoter   or suppressor, thus, it’s function may vary in different normal and tumor tissues and 
may be cell- and tumor-type specific. Therefore, the role of SIRT3 as tumor promoter or 
suppressor should not be generalized, but should be examined in each cancer type separately to 
determine whether SIRT3 functions as a tumor promoter or suppressor. Additionally, a tumor’s 
microenvironment, and its genomic dysregulation and signaling cascades, all differ from one 
tumor to another, and even from one patient to another within the same tumor type. Therefore, by 
looking at the bigger picture, screening cancer patients to analyze their genomic, epigenomic, 
proteomic, and metabolomic profile, seems to be necessary to help discover the dysregulated 
pathways that lead to a given disease, and thereby help maximize and personalize the therapeutic 
approaches for each patient. 
       In summary, this dissertation work highlights a novel role for sirtuins, and specifically, 
SIRT3 in head and neck cancer tumorigenesis. Our data suggest that the development of new 
therapy that specifically targets SIRT3, may be promising and helpful in the treatment of 
HNSCC, and may ultimately help improve the survival rate of head and neck cancer patients.  
FUTURE DIRECTIONS 
       The goal of personalized cancer treatment is to achieve a more potent and targeted cancer 
therapy for each individual, which would be associated with fewer side effects, and would  
improve the survival rates of cancer patients. Thus, routinely screening cancer patients for 
genomic, proteomic, and metabolomic abnormalities and dysregulated signaling cascades to 
highlight important alterations, might help identify useful targets for personalized cancer therapy 
and more successful cancer treatment. Our data support an overexpression of SIRT3 in a majority 
of the oral cancer tissue. Therefore, in future directions our studies will be focusing on evaluating 
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large numbers of SIRT3 expression in tissue specimens obtained from head and neck cancer 
patients. We would like evaluate the databases associated with each tissue sample, to analyze 
patient demographics, including collect data that would include age, sex, medical history, alcohol 
and smoking status, HPV status, treatment used, and treatment outcomes. This would help to 
further determine if SIRT3 expression levels are strongly associate with HNSCC, and whether 
SIRT3 levels can be used as a biomarker/risk factor for diagnosing and evaluating treatment 
outcomes for patients with head and neck cancer.  
       In addition, our preliminary in vitro SIRT3 inhibitor studies support the development of new 
specific SIRT3 inhibitors that could aid in the treatment of patients suffering from head and neck 
cancer, and other cancer types that also possess high expression of SIRT3 as part of their genomic 
dysregulation. In this regard, we are still working on developing and testing a new generation of 
the SIRT3 inhibitor, LC-0296, that would be more potent and chemically stable for use within in 
vivo settings. We also generated a GPF-tagged stable cell line from the aggressive laryngeal 
metastatic UM-SCC-17B cell line, to be able to monitor the effect of the newly developed SIRT3 
inhibitor on tumor cells in vivo (Figure 6.2).   
       The cellular localization of SIRT3 has also been controversial. Most reports support a 
mitochondrial localization [21,22,23,24,25,26,27], and some suggest a shuttling from the 
mitochondria to the nucleus or even a nuclear localization for SIRT3 that undergoes 
transportation to the mitochondria upon cellular stress [28,29,30]. Therefore, we sought to 
investigate the localization of SIRT3 in HNSCC cells in the presence or absence of cellular stress, 
as an initial step for future studies to help identify targets for SIRT3 deacetylation. Our 
preliminary data suggest that SIRT3 is a mitochondrial protein in HNSCC cells in the presence or 
absence of cisplatin treatment (Figure 6.3). In addition, our collaborators at UCSF, Eric Verdin 
and his colleagues, are experts in mitochondrial biology and acetylome analyses. Thus, we look 
forward to continuing this collaboration, to identify novel SIRT3 substrates in the context of 
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HNSCC to identify putative targets that might explain the prosurvival role of SIRT3 in head and 
neck cancer.  
 
 
 
 
 
 
 
 
 
Figure 6.1: Inhibition of SIRT3 enzymatic activity has no additional effects on ROS levels in 
the context of stable SIRT3 suppression in HNSCC cells. ROS levels were measured in UM-
SCC-17B cells that were stably transduced with scrambled-short hairpin RNA (Scr-shRNA) or 
SIRT3-shRNA after 10 days of selection using Puromycin, and after treatment with or without 
LC-0296 (50 µM) for 12 h.  
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Figure 6.2: The HNSCC cells (UM-SCC-17B) GFP-stable cell lines. (A) Immunoblots 
showing SIRT3 expression and GFP levels in 2 clones from the UM-SCC-17B cell line that were 
stably transduced with scrambled-short hairpin RNA (Scr-shRNA-GFP) or SIRT3-shRNA-GFP 
after 10 days of selection using Puromycin. β-Actin served as loading control. (B) Fluorescent 
images showing stable transfection with the Scr-shRNA-GFP and SIRT3-shRNA-GFP in UM-
SCC-17B cells.  
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Figure 6.3: SIRT3 cellular localization. HNSCC (UM-SCC-1) cells were either treated with or 
without cisplatin (50 µM) for 8 h, stained with the mitochondrial marker, MitoTracker (red), and 
immunostained for SIRT3 (FITC, green), and the nucleus with DAPI (blue). Yellow represents 
colocalization of SIRT3 to the mitochondria (Original magnification x1000).  
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